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A B S T R A C T
SOS1 and SOS2 are the most universal and widely expressed family of guanine exchange factors (GEFs) capable
or activating RAS or RAC1 proteins in metazoan cells. SOS proteins contain a sequence of modular domains that
are responsible for different intramolecular and intermolecular interactions modulating mechanisms of self-
inhibition, allosteric activation and intracellular homeostasis. Despite their homology, analyses of SOS1/2-KO
mice demonstrate functional prevalence of SOS1 over SOS2 in cellular processes including proliferation, mi-
gration, inflammation or maintenance of intracellular redox homeostasis, although some functional redundancy
cannot be excluded, particularly at the organismal level. Specific SOS1 gain-of-function mutations have been
identified in inherited RASopathies and various sporadic human cancers. SOS1 depletion reduces tumorigenesis
mediated by RAS or RAC1 in mouse models and is associated with increased intracellular oxidative stress and
mitochondrial dysfunction. Since WT RAS is essential for development of RAS-mutant tumors, the SOS GEFs may
be considered as relevant biomarkers or therapy targets in RAS-dependent cancers. Inhibitors blocking SOS
expression, intrinsic GEF activity, or productive SOS protein-protein interactions with cellular regulators and/or
RAS/RAC targets have been recently developed and shown preclinical and clinical effectiveness blocking
aberrant RAS signaling in RAS-driven and RTK-driven tumors.
1. Introduction
RAS proteins are essential signal transduction regulators controlling
signaling pathways that regulate a large variety of biological processes
including cell proliferation, differentiation, migration and survival in
different tissues and cell types, or at different developmental stages
[1,2]. These small GTPases are continuously cycling between inactive
(RAS•GDP) and active (RAS•GTP) conformations in a process modulated
by negative (GTPase Activating Proteins, RASGAPs) and positive
(Guanine nucleotide Exchange Factors, RASGEFs) regulators. Among
the main mammalian RASGEF families (SOS, GRF and GRP), SOS1 and
SOS2 are the most widely expressed and functionally relevant GEFs
regarding to RAS and RAC activation by upstream cellular signals
[1,3–6].
The Son of sevenless (dSos) gene was first discovered in Drosophila
melanogaster as a specialized RAS activator acting downstream of the
Sevenless receptor tyrosine kinase (RTK) in signaling pathways con-
trolling ommatidia development in the fly’s compound eye and various
SOS homologues were subsequently found in other species, from
Caenorhabditis elegans up to mammals [7–12].
The two mammalian orthologues of SOS (SOS1 and SOS2) code for
highly homologous proteins able to stimulate GTP/GDP exchange on
cellular RAS and RAC proteins in the context of multiple different sig-
naling pathways initiated by a great variety of different cellular surface
RTKs [1,5,6]. They display a modular structure featuring conserved
distribution of specific, functional domains along their N-, middle-, and
C-terminal regions [6]. Different intramolecular domain-domain inter-
actions as well as direct interactions between distinct cellular proteins
or lipid molecules and individual SOS modular domains mediate the
regulatory mechanisms controlling the self-inhibition and the allosteric
activation of SOS GEF activity as well as the intracellular homeostasis
and stability of the SOS proteins [13–16].
RAS activation by point mutations is known to lead to a variety of
pathological alterations including multiple tumor types (sporadic mu-
tations) and various developmental syndromes (inherited mutations)
[17–19]. On the other hand, it is also conceivable that other potential,
alternative activation mechanisms, including hyperactivation of RAS-
GEFs or dysregulation of other components of RAS-mediated signaling,
may also result in physiological or pathological alterations.
The similar protein structures and expression patterns of SOS1 and
SOS2 made it initially difficult to ascertain their specific functional
properties but most studies suggest a dominant functional role of SOS1
over SOS2 in various physiological and pathological contexts. Initial
analyses of constitutive knock-out (KO) mouse strains showed tht SOS1
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constitutive-null animals die during mid-gestation whereas adult SOS2-
KO mice are viable and fertile [20–22]. The later use of conditional
SOS1-null mutants made it possible to bypass the lethality of homo-
zygous SOS1-null mutations and to analyze the functional specificity
and/or redundancy of SOS1 and SOS2 in adults under various physio-
logical or pathological conditions [23,24]. Interestingly, SOS1/2-DKO
animals die precociously whereas single SOS1-KO or SOS2-KO mice are
viable, suggesting functional redundancy between SOS1 and SOS2 for
lymphopoiesis, organismal homeostasis and survival [23]. Further-
more, comparisons between primary mouse embryonic fibroblasts
(MEFs) extracted from SOS1-KO and SOS2-KO mice have documented
the functional prevalence of SOS1 over SOS2 in control of critical cel-
lular physiological processes including proliferation, migration, in-
flammation and maintenance of intracellular redox homeostasis
[25–27]. Moreover, the use of SOS1/2-DKO mice has demonstrated that
SOS1 plays a critical role in BCR-ABL-induced leukemogenesis as well
as in homeostasis and chemically-induced carcinogenesis of the skin
[26,28,29].
A number of recent studies have also increasingly pointed to the
functional implication of SOS GEFs (particularly SOS1) in human tu-
mors and other pathologies. Thus, an important number of gain-of-
function genetic alterations or mutations in different SOS1 (and rarely
SOS2) domains have been identified in inherited RASopathies such as
Noonan syndrome (NS) or hereditary gingival fibromatosis (HGF-1)
[30,31], as well as in various sporadic human cancers including, among
others, endometrial tumors (UCEC) and lung adenocarcinomas (LUAD)
[32–37]. These observations, together with the fact that SOS depletion
in KO cell lines and mouse models reduces specific tumorigenic pro-
cesses mediated by RAS [26,38] or RAC [28,29], and is also associated
with increased intracellular oxidative stress and mitochondrial dys-
function [25], support the hypothesis that the SOS1/2 GEFs may con-
stitute relevant biomarkers and/or therapy targets in KRAS-driven (and
also EGFR-driven) tumors. This view is reinforced by the seminal de-
monstration that SOS-mediated activation of WT RAS is critical for the
development of RAS-mutant tumors [39–41]. Recent research efforts
from multiple academic and industry platforms have focused on de-
veloping specific inhibitors capable of blocking either SOS1/2 expres-
sion, GEF activity or productive interactions with RAS/RAC targets and
other cellular regulators. Fortunately, a number of these SOS inhibitors
have proven efficacious in various cell and xenograft models of RAS-
driven and RTK-driven tumors, and some of them have even recently
reached the clinic [42–52].
In this review, we summarize our current understanding of the
structure and regulation of SOS genes and proteins and we also describe
various specific functional roles played by the SOS1/2 GEFs in different
cells and tissues under physiological, healthy conditions. We also re-
view the variety of genetic alterations recently found in SOS1 (and
rarely SOS2) in association with inherited developmental syndromes
and sporadic human cancers. Finally, we focus on the potential use-
fulness of SOS GEFs as markers or therapy targets for RAS-dependent
tumors and the recent development of specific SOS inhibitors that may
be clinically useful for the management of RAS-dependent and/or RTK-
dependent tumors featuring aberrant RTK-SOS-RAS-ERK signaling.
2. The SOS gene family
About three decades ago, studies on the development of the com-
pound eye in D. melanogaster led to the discovery of the Son-of-Sevenless
gene (dSos) [7,11,12] and various dSos homologues were later reported
in more complex biological systems including the nematode C. elegans
[9], zebrafish (Danio rerio) [53,54], or mouse and human mammalian
cells [5,6,8,10].
2.1. Genomic structure and organization
Whereas the D. melanogaster and C. elegans genomes harbor a single
Sos gene (7 and 19 exons, respectively), two homologs (SOS1 and
SOS2), located in different chromosomes exist in the genomes of zeb-
rafish, mice and humans (https://flybase.org/; https://www.
wormbase.org/; https://zfin.org/; www.ensembl.org/). Using the
human SOS genes as reference for comparison, the ENSEMBL database
lists 264 orthologues and 26 paralogues for the hSOS1 gene and 188
orthologues and 26 paralogues for the hSOS2 gene.
The zebrafish homolog of SOS1 (Chr11 position: 45,436,703 -
45,463,766; 15 exons) is located in chromosome 11 whereas its SOS2
homolog (Chr13 position: 36,638,955 -36,663,358; 23 exons) maps to
chromosome 13. On the other hand, the mSOS1 mouse gene is posi-
tioned on chromosome 17 (Chr17 position: 80,393,751 - 80,480,452;
22 exons) and mSOS2 on chromosome 12 (Chr12 position: 69,583,762 –
69,681,852; 23 exons), whereas the hSOS1 and hSOS2 human SOS
homologues are located, respectively, on chromosome 2 (Chr2 position:
38,981,396 – 39,124,345; 23 exons) and chromosome 14 (Chr14 po-
sition: 50,117,130 – 50,231,578; 23 exons). The overall span of the
genomic regions occupied by the SOS1 and SOS2 loci varies widely in
different organisms but the intron/exon distribution of all these genes is
highly conserved, with various specific exons coding for the conserved
protein modules that conform the overall, sequential protein domain
structure of the SOS1/2 GEFs [5,6] (Fig. 1).
2.2. Non-coding regulatory elements
Focusing only on the non-coding regulatory regions of mammalian
SOS genes, the Ensembl Regulatory Build database (https://www.
ensembl.org/info/genome/funcgen/regulatory_build.html) indicates
that the hSOS1 gene contains one promoter region and several pro-
moter-flanking regions located between exon 1 and exon 2 and between
exon 8 and exon 22. In addition, 9 enhancer sites, located between exon
2 and exon 11, as well as 9 CTCF (CCCTC-Binding factor) binding sites
distributed from exon 1 to exon 17 are suggested (https://www.
ensembl.org/Homo_sapiens/Location/View?db=core;g=
ENSG00000115904;r=2:38981396-39124345). Similarly, mSOS1 dis-
plays one promoter region, 6 promoter-flanking regions distributed
from exon 1 to exon 11, and 8 enhancer sites mainly located between
exon 1 and exon 2. In addition, 7 CTCF sites located between exons 1
and 6 are proposed for mSOS1 gene (https://www.ensembl.org/Mus_
musculus/Location/View?db=core;g=ENSMUSG00000024241;r=
17:80393751-80480453) (Fig. 1).
The hSOS2 gene (chromosome 14) shows some distinctive features
in comparison to the hSOS1 promoter. Two promoters are defined for
this gene in the database, one located upstream of the transcription
starting site and another one at a 3’ site. 4 promoter-flank sites are also
described at locations between exon 1 and exon 2. In addition, 4 en-
hancers (located between exons 13 and 19) and 5 CTCF sites (between
exons 1 and 2), are also defined by Ensembl Regulatory Build (https://
www.ensembl.org/Homo_sapiens/Location/View?db=core;g=
ENSG00000100485;r=14:50117130-50231578). Finally, mSOS2 gene
shows one promotor and four promoter-flank regions located between
exon 1 and exon 5 (https://www.ensembl.org/Mus_musculus/
Location/View?db=core;g=ENSMUSG00000034801;r=
12:69583762-69681852). In addition, one enhancer, located near exon
16, and 5 CTCF sites are also identified (Fig. 1).
In silico analysis using the Transfac database (http://gene-
regulation.com/pub/databases.html#transfac) predicts specific
binding sites for a variety of transcription factors within defined regions
of the promoters of the hSOS1 and hSOS2 genes. However, the only
direct experimental evidence obtained so far corresponds to the de-
monstration (by means of ChIP-seq) of the specific binding of the AhR
receptor to a defined region of the hSOS1 promoter [55]. On the other
hand, no experimental evidence is yet available in the literature for any
transcription factor binding to the hSOS2 promoter.
The hSOS1 and mSOS1 genes contain highly conserved 5'-un-
translated regions (5’-UTR) (87 and 46-nt long, respectively, showing
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90.2% identity in the first 46 nt sequences). hSOS1 and mSOS1 also
possess 3’-UTR of 4428 and 4430 nt long, respectively, that share 71.9%
identity. On the other hand, the hSOS2 and mSOS2 loci possess similar
5’-UTR regions (295 and 251-nt long, respectively, with 74% nt se-
quence homology in their 251 initial residues) as well as 3’-UTR of 1214
and 1357 nt respectively, sharing 65.9% nucleotide identity in their
initial 1214 residues and overall 66.4% similarity if the complete UTR
regions are compared. Proposed mRNA secondary structures (likely to
participate in translational regulation of the SOS1 and SOS2 genes in
mice and humans) generated for these UTR sequences by the RNAfold
program from the Vienna RNA package (https://www.tbi.univie.ac.at/
RNA/) are shown in Supplementary Fig. 1. The significant similarities
shown by the primary and secondary structures of the UTR regions of
the mouse and human SOS1 and SOS2 genes suggest also significant
similarities in the mechanisms of transcriptional regulation played by
these mRNA sequences in mammalian SOS genes.
2.3. SOS gene transcription
Well defined, full-length mRNA transcripts for the SOS1 and SOS2
genes have been identified for each of these genes in vertebrate species
from fish to mammals (Fig. 1). In addition, the plethora of new se-
quencing data from many different human cell types and tumors that
has been recently deposited in different databases supports the
existence of a large number of potential, alternative transcripts or iso-
forms for both SOS1 and SOS2. Updated summaries of transcript data
are available in the Ensembl portal for hSOS1 (https://www.ensembl.
org/Homo_sapiens/Gene/Summary?db=core;g=
ENSG00000115904;r=2:38981549-39124345) and hSOS2 (https://
www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=
ENSG00000100485;r=14:50117130-50231578).
Computational predictions of alternative splicing events are also
updated in the Alternative Splicing Gallery portal (https://
brcwebportal.cos.ncsu.edu/asg/index.php?lookupType=match&
lookupValue=ENSG00000115904) and for hSOS2 (https://
brcwebportal.cos.ncsu.edu/asg/index.php?lookupType=match&
lookupValue=ENSG00000100485). However, direct experimental
evidence supporting the real existence of many of the predicted, al-
ternatively spliced mRNA species (as well as corresponding, potentially
altered protein products) or non-coding RNAs, is scarce or nonexistent
in most cases and, therefore, a comprehensive analysis in this regard is
certainly warranted at this time. Our laboratory has described the
identification in some human tissues (but not in corresponding mouse
tissues) of two hSOS1 isoforms (Isf I and Isf II, differing only by the
presence in Isf II of an extra 15-amino acid sequence located within the
C-terminal proline-rich motif) that display very different biochemical
and biological potencies [56]. In addition, the immunoblot detection
(in addition to the full length SOS1 protein band) of a number of
Fig. 1. Genomic structure, organization, and intron/exon
distribution of SOS1 and SOS2 genes in vertebrate species.
Genomic organization of SOS1 (upper panel) and SOS2 (lower
panel) loci in vertebrate species including zebrafish, mouse
and human as indicated. Figure assembled using current data
from the Ensembl genome browser database (http://www.
ensembl.org/index.html). Chromosomal location, chromo-
some strand (+ or −) used for transcription, and size (Kb) of
the genomic stretches containing the SOS1 and SOS2 loci are
also indicated for each species. Intron/exon distribution and
correspondence of the coding exons (solid vertical boxes) to
the conserved modular domains (color coded) of full-length
SOS1 and SOS2 proteins is indicated by similarly colored
dotted lines in each case. Non-coding regulatory regions in
the mammalian SOS genes, including 3'-UTR (empty boxes),
promoters (red horizontal box), promoter-flanking regions
(light green), enhancers (dark yellow) and CTCF binding sites
(blue) are also indicated by the corresponding, horizontal
colored boxes.
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smaller molecular weight bands is also suggestive of the existence of
alternatively spliced forms of SOS1 in different tissues or develop-
mental stages [57].
2.4. Genetic polymorphisms
The NCBI database for single nucleotide polymorphisms (SNPs) lists
thousands of genomic polymorphisms (including del, delins, ins, mnv
and snv) associated to hSOS1 (https://www.ncbi.nlm.nih.gov/snp/?
term=SOS1) and hSOS2 (https://www.ncbi.nlm.nih.gov/snp/?term=
SOS2) that may give rise to multiple structural or functional con-
sequences (intron or exon variants, etc) depending on their location on
coding or non-coding regions and are classified based on their clinical
consequences as benign, likely-benign, likely-pathogenic, pathogenic,
or of uncertain significance. Interestingly, only 44 pathogenic or likely
pathogenic SNPs in hSOS1, mainly associated to RASopathies like NS
and HGF-1 or sporadic tumors like lung adenocarcinoma, uterine
corpus endometrial carcinoma or glioblastoma multiforme and 4 SNPs
in hSOS2 (associated with NS) are identified in this database.
2.5. Physiological expression patterns
SOS1 and SOS2 appear to be ubiquitously expressed, as the presence
of specific RNAs or proteins for those genes is detectable in practically
all human cells, organs and tissues tested. However, the actual levels of
mRNA and proteins for hSOS1 and hSOS2 differ markedly depending on
the specific organ or tissue analyzed.
Based on transcriptomic analyses across all major organs and tissue
types in the human body, the Consensus dataset of the Human Protein
Atlas database indicates that the highest mRNA expression levels re-
ported for hSOS1 (https://www.proteinatlas.org/ENSG00000115904-
SOS1/summary/rna) and hSOS2 (https://www.proteinatlas.org/
ENSG00000100485-SOS2/summary/rna) are detected in the para-
thyroid gland, and variable levels of quantitatively significant mRNA
expression levels are also detected in all other organs and solid tissues,
with hematological cells and tissues showing the lowest relative levels
of RNA expression for these two RASGEFs. Focusing only on blood cell
types, these consensus transcriptional profile analyses show that the
relative hSOS1 mRNA expression levels are highest in natural killer
(NK) and CD4/8-positive cells whereas this expression is almost absent
in basophils (https://www.proteinatlas.org/ENSG00000115904-SOS1/
blood). In contrast, hSOS2 mRNA is highly expressed in both basophils
and NK cells (https://www.proteinatlas.org/ENSG00000100485-SOS2/
blood).
Interestingly, recent, highly sensitive, single cell transcriptome data
from different mouse organs and tissues (Tabula Muris database,
https://tabula-muris.ds.czbiohub.org/) or from specific mouse and
human lung cell types (https://research.cchmc.org/pbge/lunggens/
genequery_dp.html?spe=HU&tps=pnd1&geneid=SOS1; https://
research.cchmc.org/pbge/lunggens/genequery_dp.html?spe=HU&
tps=pnd1&geneid=SOS2) identify endothelial cells as the specific cell
type expressing the highest level of hSOS1 mRNA.
The datasets for SOS1 and SOS2 protein expression levels (based on
immunological detection methods are necessarily less quantitatively
accurate than the corresponding mRNA datasets for the same tissues
due to background signals and/or the partial specificity of some of the
antibody reagents but still roughly similar profiles of protein expression
are observed in most cases. Interestingly, in contrast to the mRNA
profile datasets, the relative levels of hSOS1 and hSOS2 proteins de-
tected in blood cells and tissues are in the same quantitative range than
those found in solid tissues (https://www.proteinatlas.org/
ENSG00000115904-SOS1/tissue; https://www.proteinatlas.org/
ENSG00000100485-SOS2/tissue) or cells (https://www.proteinatlas.
org/ENSG00000100485-SOS1/cell; https://www.proteinatlas.org/
ENSG00000100485-SOS2/cell). Interestingly, an elegant quantitative
proteomic analysis of the core components of the EGFR-MAPK pathway
across different cell types has recently revealed that the absolute
abundance of SOS1 and SOS2 proteins (2000-5000 copies per cell) is far
lower than that of most other core proteins (50000-70000 copies per
cell) in the EGFR-MAPK pathway, suggesting that the low-abundance of
SOS GEFs may serve as a regulatory bottleneck in this pathway [58].
2.6. Expression in pathological contexts
The alterations of RNA and protein levels of SOS1 and SOS2 that are
expressed in a variety of human tumors and cell lines are updated and
quantitated in a timely fashion in the Protein Atlas database (https://
www.proteinatlas.org/ENSG00000115904-SOS1/pathology; https://
www.proteinatlas.org/ENSG00000100485-SOS2/pathology). An over-
view of the normalized, baseline RNA expression measurements (RNA-
seq data and NX normalized units) carried out in a wide collection of
tumors affecting different organs shows variable but relatively similar
ranges of SOS1mRNA levels in most cell lines analyzed, with some lines
of myeloid origin showing the highest relative levels of expression
(https://www.proteinatlas.org/ENSG00000115904-SOS1/cell#rna).
Likewise, roughly similar levels of SOS2 transcripts are also quantitated
in the same cell line collection, with the highest levels detected in some
lines of lymphoid origin (https://www.proteinatlas.org/
ENSG00000100485-SOS2/cell#human). On the other hand, pro-
teomics analysis of a large variety of tumor cell lines detects the highest
hSOS1 protein expression in CoCM-1 cells (https://www.proteomicsdb.
org/proteomicsdb/#protein/proteinDetails/58554/expression)
whereas CAL-27 oral squamous carcinoma cells are the ones exhibiting
highest hSOS2 protein expression (https://www.proteomicsdb.org/
proteomicsdb/#human/proteinDetails/Q07890/expression).
The KERIS database, which collects data about the altered tran-
scriptional profiles of specific genes among different inflammatory
diseases and conditions (http://igenomed.org/immune/index) docu-
ments that hSOS1 expression is significantly upregulated in whole blood
cell extracts of pediatric patients with acute community-acquired
Staphylococcus aureus infection [59] and in patients with Acute Re-
spiratory Distress Syndrome (ARDS)/Acute Lung Injury (ALI) and
Sepsis; in contrast, the hSOS1 mRNA levels are very significantly
downregulated in patients who suffered severe burns or physical
trauma (http://www.igenomed.org/immune/gene?search=SOS1. In-
terestingly, the database shows a very different pattern of altered ex-
pression for hSOS2 under similar pathological conditions. In contrast to
hSOS1, the expression of the hSOS2 gene shows measurable upregula-
tion following S. aureus infection, burn, trauma and sepsis (http://
www.igenomed.org/immune/gene?search=SOS2), but very strong re-
duction in patients with ARDS/ALI http://www.igenomed.org/
immune/gene?search=SOS2).
Regarding other pathological conditions, transcriptomic analysis
from whole blood samples has detected significant downregulation of
hSOS1 gene expression upon acute ethanol exposure [60] and, cur-
iously, a recent report has also identified hSOS1 as a significantly en-
riched component of a hub of protein products from the RAS-ERK
pathway that are linked to development of human inguinal hernia [61].
2.7. miR-mediated regulation of expression
Post-transcriptional regulation of the expression of SOS1 and SOS2,
mediated by a great variety of specific miRNAs has also been reported
under physiological and/or pathological conditions in many different
cell types (Supplementary Table 1). As detailed in the miRTarBase
(http://mirtarbase.mbc.nctu.edu.tw/php/search.php#target) or the
DIANA-TarBase v8 (http://carolina.imis.athena-innovation.gr/diana_
tools/web/index.php?r=tarbasev8%2Findex/), the evidence sup-














query=) range from simple theoretical predictions of interaction be-
tween different miRNAs and defined regions, mostly belonging to the
3'-UTR, of the SOS1 and SOS2 genes, to direct experimental reports
showing that increased expression of many different miRNAs correlates
with reduced SOS1 or SOS2 expression in a large variety of normal and/
or tumoral cell types and conditions.
A great variety of different miRNAs have so far been identified that
are able to modulate either SOS1 or SOS2mRNA expression in different,
normal or tumoral cell types (Supplementary Table 1). The bulk of
experimental evidence identify specific sequences within the 3'-UTR of
the hSOS1/2 genes as the targets recognized by the different binding
miRNAs identified, although, at least in theory, some other regions of
the SOS1 and SOS2 genes may also be recognized for binding by specific
miRNAs. Packing of the miRNAs into exosomes may be relevant for
their SOS1/2 regulatory functions as indicated by a report showing that
macrophage-derived miR-155-containing exosomes suppress fibroblast
proliferation during cardiac injury through its interaction with hSOS1
[62].
Although most published studies on miRNAs targeting SOS1/2 ex-
pression have focused on their inhibitory effects on different tumor-
derived cell lines (Supplementary Table 1), miR-mediated down-reg-
ulation of SOS1 expression is also functionally relevant in non-tumoral
contexts such as the reduction of fibroblast proliferation upon cardiac
injury [62], the reduction of fibrogenic activity of human gingival fi-
broblasts [63], or the induction of cytoxicity by silver nanoparticles in
human dermal fibroblasts [64].
Fig. 2. Structure, conformation and regulation of SOS proteins.
(A) Primary structure of human SOS1 and SOS2 proteins. HD: Histone-like Domain; DH: Dbl Homology; PH: Pleckstrin Homology; HL: Helical Linker; REM: Ras
Exchange Motif containing the allosteric site, CDC25H: homologous to Cell Division Cycle; PR: Proline-Rich, containing several SH3-binding motifs (vertical lines).
(B) In resting conditions, the N-terminal DH-PH tandem and the C-terminal PR region mediate independent mechanisms maintaining SOS in an auto-inhibited state.
Self-inhibition is relieved through recruitment of SOS proteins to the plasma membrane facilitated by the interaction of the HD and PH domains with membrane
phospholipids and the interaction of the C-terminal PR region with SH3 domains of adaptor proteins like GRB2 that are also complexed through SH2 domains to pTyr
residues of agonist-stimulated RTKs. Sequential, coordinated action of the REM allosteric site (activated by RAS•GTP) and the CDC25H catalytic site (reorienting its
helical hairpin, represented here by a red crescent shape, to facilitate GDP/GTP exchange) creates a positive feedback loop of SOS activation. RAS•GTP accumulation
at the membrane is also responsible for activation of downstream RAS signaling and triggering of a negative feedback regulatory loop blocking the association of SOS
with GRB2 and inhibiting SOS function through ERK and RSK2 action. (C) The intermolecular interaction of the SOS PR domain with adaptor proteins such as GRB2
and E3B1 determines their recruitment to the specific subcellular locations where activated SOS GEF proteins meet and activate their specific RAS or RAC targets.
GRB2:SOS interaction leads to RAS activation in the inner side of the membrane. E3B1-EPS8-SOS interaction leads to activation of RAC1 molecules in actin filaments
of membrane ruffles.
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Despite the high homology existing between the 3’-UTR sequences
of SOS1 and SOS2, it is relevant to notice that the sets of miRNAs re-
ported to bind to either gene are very different among themselves,
suggesting a high degree of specificity for the mechanisms of miRNA-
mediated regulation of the expression of the SOS1 and SOS2 genes.
Indeed, only miR-148a has been reported to target both the SOS1 and
SOS2 genes, although binding to different, non-homologous regions of
the 3'-UTR of the two genes [65] (Supplementary Table 1).
2.8. Drug-mediated Regulation of Expression
A wide array of natural compounds or drugs previously known to
exhibit antitumor activity have also been recently reported to alter the
expression levels, and consequently the intracellular biological activity,
of the SOS1 and/or SOS2 RASGEFs. Most of these compounds cause
reduced expression levels of SOS1 protein in a variety of tumor cell
types, although in some cases they are also reported to inhibit SOS2
protein expression (Supplementary Table 2). Of note, carcinogenic en-
vironmental pollutants such as 2,3,7,8-tetrachlorodibenzodioxin show
the opposite effect, triggering increased expression of SOS1 in HepG2
cells [55].
3. SOS Protein structure and regulation
Analyses of the primary amino acid sequences [1,5,6,13,66] and the
three-dimensional (3D) structures available for SOS1 and SOS2 proteins
in various databases including the Protein Data Bank (https://www.
rcsb.org) have provided the basis for our current understanding of the
structural and conformational changes involved in the regulation of the
cellular functions of these SOS proteins [5,13–16].
3.1. Modular domain structure
The primary structure of the SOS1/2 proteins displays a sequential,
linearly organized modular structure featuring conserved distribution
of specific functional domains containing protein motifs that possess
specific biochemical properties and binding affinities for various in-
tracellular proteins or lipids. The overall structure of SOS proteins can
be divided into three distinct tiers corresponding to their C-terminal,
central and N-terminal regions, and the regulation of the GEF activity of
these proteins originates from the collective operations and interactions
mediated by the modular domains within those regions [13–16,67]
(Fig. 2A).
In the native cytosolic state the guanine nucleotide exchange ac-
tivity of SOS is auto-inhibited through independent blockade mechan-
isms mediated by the N-terminal and the C-terminal regions, and its
GEF activity only becomes activated upon membrane recruitment [68].
Different intra-molecular domain-domain interactions, as well as direct
inter-molecular interactions between distinct cellular proteins or lipid
molecules and various individual SOS modular domains mediate the
multilayer regulatory mechanisms that control the processes of self-
inhibition and the release of the blockade of the catalytic activity of
SOS, as well as the intracellular homeostasis and stability of these key
RAS activator proteins [13,15] (Fig. 2B).
Basically, the N-terminal region is responsible for maintenance and
release of auto-inhibitory mechanisms as well as subcellular membrane
location of the SOS proteins. The central region contains the domains
responsible for allosteric modulation and catalytic activity functions
controlling the activation (GTP loading) of RAS proteins. The C-term-
inal domain contains several proline-rich (PR) motifs responsible for
various subcellular protein-protein interactions (PPI) that are critical
for fine regulation of the processes leading to intracellular activation of
RAS or RAC proteins, and subsequent downstream signaling. The PR
domain also exerts an auto-inhibitory role over the central catalytic
module under native, unstimulated cellular conditions (Fig. 2B).
3.2. The Amino-terminal Region of SOS
The initial N-terminal stretch of ~550 amino-acids in SOS proteins
contains three well-defined structural domains: the Histone-like
Domain (HD), the Dbl Homology domain (DH), the Pleckstrin
Homology domain (PH) and the Helical Linker (HL) (Fig. 2A). Together,
these 3 domains act cooperatively modulating SOS GEF auto-inhibition
as well as the firm attachment of full-length SOS proteins to the inner
side of plasma membrane and the subsequent release of their initial,
native auto-inhibition.
The HD domain (~110 aa´) contains two tandem folds with
homology to histone H2A [69] and plays the dual (negative) regulatory
role of directly participating in the occlusion of the allosteric site in the
central region, and also stabilizing the basal inhibitory conformation of
the DH-PH tandem module (~350 aa´ located immediately before the
catalytic module) that prevents SOS GEF activation [70] (Fig. 2B). The
HD has also been recently shown to interact with the CSN3 subunit of
the COP9 signalosome [71] which functions in the ubiquitin-protea-
some pathway [72] suggesting a role of this domain as regulator of the
stabilization and intracellular homeostasis of SOS1 protein.
Consistent with the recognized roles of the DH domains typically
found in other GEFs as activators of proteins the RAC/RHO/CDC42
family [73], the SOS DH domain has also been implicated in coupling
RAS activation to the activation of RAC, although the exact mechanistic
details still remain unclear [13,66,74].
Both the HD and the PH domains have been shown to bind to spe-
cific lipids in membranes, an essential step in the release of SOS GEF
autoinhibition [75]. The HD has the ability to interact with negatively
charged membrane phospholipids through a conserved region (similar
to the H2A DNA-binding surface) possessing positive electrostatic po-
tential [76]. On the other hand, the PH domain (Fig. 2) binds to
phosphoinositol phosphates with higher affinity for PIP3 than for PIP2
[77].
3.2.1. SOS N-term-mediated auto-inhibition and release
Indeed, the HD and the DH-PH unit are conformationally coupled
[70] and all their concerted lipid interactions are critical for growth
factor-driven SOS membrane targeting and subsequent RAS activation.
Crystal structure analyses have shown that the DH and PH domains
together are integrated into a structural module constituting a func-
tional unit that directly participates in control of SOS intramolecular
inhibition and its interaction with the cell membrane [70,76,78]. Be-
sides favoring SOS1 anchorage to the cell membrane [77], the DH-PH
tandem exerts a negative allosteric control by reducing the catalytic
activity of SOS [79].
Crystallographic and biochemical analyses of a truncated SOS con-
struct containing all but the C-terminal PR domain of SOS showed that,
under native conditions, the SOS DH-PH modular tandem blocks the
allosteric binding site (where RAS•GTP binds to the REM domain) thus
suppressing the GEF activity of the SOS catalytic module [79] (Fig. 2B).
This inhibitory effect is relieved through the interaction of different N-
terminal domains with membrane phospholipids [70,75,78,80]. The
simultaneous binding of the PH domain with membrane phosphoino-
sitol phosphates, together with the electrostatic interactions between
the positively charged HD surface and negatively charged membranes,
releases the inhibitory conformation of SOS resulting in a productive
reorientation of the protein at the membrane and increased accessibility
to RAS binding (Fig. 2B). The inducible association of HD with mem-
branes contributes to the catalytic GEF activity of SOS by forcing that
domain to adopt a conformation that destabilizes the self-inhibitory
state (Fig. 2). Thus, the HD plays a critical role in controlling the cat-
alytic output of SOS by coupling membrane recruitment to the release
of self-inhibition [78].
Consistent with the negative regulatory role of the SOS N-terminal
region, several reports have described germline gain-of-function mu-
tations in this region (mostly located in the DH-PH tandem domain)
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associated to ~13-20% of patients with Noonan Syndrome (NS) [31],
an autosomal dominant developmental disorder characterized by hy-
peractivation of the RAS-RAF-MEK-ERK pathway [31,81,82]. In any
event, it should be emphasized that the regulatory mechanisms of the
N- and C-terminal regions of SOS protein are independent of each other
and full autoinhibition requires both the N- and C-terminal inhibitory
modes [15].
3.3. SOS catalytic and allosteric domains
The central region of the SOS proteins (approximately, residues 550
to 1050) located between the Helical Linker (HL) (~30-40 aa´) and the
C-terminal (PR) region (about 300 aa´), constitutes the catalytic core of
the SOS GEF proteins [6,13,16]. The catalytic module, frequently de-
signated as SOScat [83] contains two distinct domains: the REM (Ras
Exchange Motif) housing the allosteric site, and the CDC25H domain
(homologous to Cell Division Cycle 25, a RASGEF in yeast) containing
the catalytic site with specific ability to act on targets of the Ras sub-
family of proteins. The sequence of the CDC25H domain is highly
conserved from fungi up to mammals whereas the sequence of the REM
domain is more variable across evolution [84] (Fig. 2A,B).
3.3.1. The CDC25H catalytic domain. SOS GEF activity promotes
nucleotide release
Analysis of the crystal structure of 1:1 RAS:SOScat complexes pro-
vided the basic clues to understand the mechanisms whereby the SOS
GEFs promote exchange of guanine nucleotides on RAS targets, in-
dicating that the SOS proteins induce a wide opening of the active site
of RAS, displacing bound nucleotide and thus facilitating its release
from RAS [13,85].
The structure of 1:1 RAS:SOScat crystals showed that the SOScat
partner of the complex interacts with, and stabilizes, the nucleotide-free
form of RAS via an interface involving the Switch I and Switch II regions
of RAS [85,86] where Switch II provides the main anchoring point for
SOS. In this structure, a helical hairpin element protruding from the
main body of the CDC25H domain gets inserted between the Switch I
and Switch II of RAS, acting as a molecular wedge prying open the
active site of RAS and forcing the release of any previously bound the
nucleotide (Fig. 2B). In this context, the SOS GEF activity of the
CDC25H domain does not impose any preference on whether RAS is
reloaded with GTP or GDP. Once the nucleotide bound to RAS is re-
leased by the GEF, RAS is reset by GTP binding driven by the higher
intracellular concentrations of GTP over GDP.
3.3.2. The REM domain. SOS allosteric activation and positive feedback
loop
In addition to the above mechanisms mediated by CDC25H, the
study of crystals containing a 2:1 complex of RAS and SOScat [83] led
to the discovery that the GEF activity of the CDC25H domain is also
allosterically activated by RAS•GTP through the action of the neigh-
boring REM domain. The structure of these crystals revealed that nu-
cleotide-free RAS was bound to the active site in the CDC25H domain as
in the 1:1 RAS:SOScat complexes, but that a second RAS•GTP molecule
was bound to a distal site wedged between the REM and CDC25H do-
mains (Fig. 2B). Comparing the structure of isolated SOScat to that of
the RAS-SOScat complexes clarified the mechanism of this allosteric
activation. In the native, RAS-free state of SOS proteins, the helical
hairpin of CDC25H is tilted towards the active site of SOS thereby
constricting the site where SOS is supposed to engage Switch II of nu-
cleotide-free RAS. This suggests that RAS binding to the active site of
SOS requires the helical hairpin to be pulled back. In this regard, the
allosteric binding of RAS•GTP to SOS facilitates the rotation and
opening of the helical hairpin, thus freeing the catalytic site to bind RAS
through the switch II [87,88].
The sequential, coordinated action of the REM and CDC25H do-
mains through the above described mechanisms creates a positive
feedback loop of SOS activation [14] whereby the binding of an active
RAS on the allosteric REM site of a native, RAS-free SOS molecule
generates an allosterically activated SOS CDC25H that then produces
active RAS•GTP, which in turn returns to the allosteric REM site of the
minimally active allosteric RAS-devoid SOS, thereby activating SOS.
This loop couples with the membrane-binding-mediated release of au-
toinhibition in cells [14,89–91] to activate SOS in such a way that only
a small fraction of active SOS is needed to produce active RAS•GTP
[79,89–91]. In this way, once a single molecule of SOS is allosterically
activated by RAS•GTP at the membrane, hundreds of RAS molecules can
then be processively activated by that SOS molecule [13]. Thus, RAS is
by itself an essential determinant of SOS regulation [79].
3.4. Carboxy-terminal Segment of SOS
The approximately 300 aa´-long region of the C-terminal region of
SOS proteins has an overall disordered structure adopting a left-handed
polyproline type II helix conformation [15,92] that complicates crys-
tallization and purification of full length SOS proteins. Specifically, the
sequence of this carboxyl-terminal PR region features four bona fide
Proline-Rich motifs (PΨΨPPR) as well as other imperfectly matching
SH3-minimal binding sites (ΨPXΨP) [93] with ability to bind to SH3
(Src Homology 3) domains present in the sequence of intracellular
adaptor proteins such as GRB2 or E3B1 [66]. Under native, un-
stimulated conditions, this adaptor-free C-terminal tail exerts an auto-
inhibitory effect (independent of that produced by the N-terminal re-
gion) on the catalytic GEF activity of native SOS proteins [94]. It is
precisely the intermolecular interaction of the SOS PR domain with
different adaptor proteins, particularly GRB2 and E3B1, which de-
termines the release of that auto-inhibition through their recruitment to
the specific subcellular locations where the activated SOS GEF proteins
meet and activate their RAS (via GRB2 interaction) or RAC (via E3B1
interaction) targets [1,5,6,13,66,74] (Fig. 2).
The possibilities of modulation of SOS GEF activity by interacting
intracellular proteins are not limited to GRB2 and E3B1. Besides these
two proteins, the SOS proteins are also able to interact through their C-
terminal region with a large number of SH3-containing adaptors or
scaffold proteins including SHC, NCK, p130Cas, EZRIN, SPROUTY,
BCR-ABL, GPCRs, LAT or 14-3-3 [13,95,96]. Updated record of all
possible partners capable of interacting with SOS1 or SOS2 in in-
tracellular protein complexes are kept in the Biogrid (https://
thebiogrid.org/112537/summary/homo-sapiens/sos1.html; https://
thebiogrid.org/112538/summary/homo-sapiens/sos2.html) and String
(https://string-db.org/) databases. Likewise, updated data concerning
the multiple different posttranslational modifications that SOS proteins
may undergo and thus alter their participation in those complexes [97]
updated data for SOS1 and SOS2 is also found in the Phosphosite da-
tabase https://www.phosphosite.org/proteinAction.action?id=5000&
showAllSites=true; https://www.phosphosite.org/proteinAction.
action?id=8108&showAllSites=true). The great variety of potential
binding partners and the many posttranslational modifications that may
alter those interactions offer multiple regulatory possibilities to mod-
ulate the processes of RAS or RAC activation by SOS1/2 in different
biological contexts.
Interestingly, alternatively spliced SOS1 isoforms affecting the
structure/disposition of some of the individual PR motifs have been
found in humans that show different SH3 binding ability, specificity
and biological potency [56,98]. The existence of alternative SOS1/2
isoforms, together with the availability of many different possible in-
tracellular adaptor/scaffold binding partners, suggests the existence of
multiple layers of fine regulation of the process of RAS and RAC acti-
vation by SOS in different biological and cellular contexts, as well as
modulation of the cross-talk between RAS and RAC activation path-
ways.
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3.4.1. SOS-RAS activation pathway and negative regulatory feedback loop
Early mutagenesis and structural studies provided most of the me-
chanistic insights explaining the interaction of GRB2 with SOS [99].
Upon stimulation of cell surface receptors by upstream agonists, the
SH3-mediated SOS1-GRB2 complexes can be recruited from the cytosol
to the inner surface of the plasma membrane through the interaction of
the SH2 domains of GRB2 with phosphotyrosine residues of the acti-
vated RTKs [1,5,6,13]. Such translocation facilitates the CDC25H do-
main of SOS1 to trigger GDP-GTP exchange on the membrane-bound
RAS molecules [6] and subsequent activation of the RAS-ERK path-
ways. The overall level of SOS GEF activation at the membrane is ba-
lanced by the reversible binding kinetics of the SOS:GRB2 interaction
[100] which can be modulated by the alternative binding of GRB2 to
many other potentially competing intracellular protein partners. Once
SOS reaches its location at the membrane, it remains there until being
actively removed by membrane endocytosis [100] (Fig. 2B,C).
The activity of this GRB2-SOS-RAS signaling pathway is ultimately
controlled by feedback mechanisms targeting SOS1. In particular,
phosphorylation of specific Ser/Thr residues of the C-terminal region of
SOS by ERK and RSK kinases is known to alter its association with GRB2
and inhibit SOS1 function, thus constituting the main mechanism re-
sponsible for the negative feedback of the RAS activation pathway
[101–106] (Fig. 2B,C). Furthermore, binding of antagonists such as
p27KIP1 or SPROUTY1-4 to GRB2 also prevents its binding to SOS1
[107]. Oxidative stress has also been shown to inhibit EGFR-SOS-RAS
signaling by activating the binding of p66SHC to EGFR and GRB2 and
promoting the dissociation of GRB2 from SOS1 [108].
3.4.2. SOS-RAC activation pathway
The differential activity of SOS over RAS or RAC targets in vivo
appears to be mostly mediated by mutually exclusive interactions with
either GRB2 or E3B1 adaptor proteins [74]. For SOS to activate RAC,
SH3-mediated SOS1-E3B1 complexes are recruited to actin filaments
found within membrane ruffles (where RAC is preferentially localized)
in an EPS8-dependent manner (through the interaction of an EPS8 SH3
domain with a PXXP domain of E3B1) [109] facilitating the DH domain
of SOS1 to catalyze GTP-GDP exchange within RAC [110]. Once linked
to actin filaments through EPS8, the EPS8-E3B1-SOS1 complex can
activate the resident RAC molecules and trigger subsequent down-
stream signals activating c-JUNK and other members of the MAPK
cascade, thus enabling actin cytoskeleton remodeling [5,111]
(Fig. 2B,C).
The mechanisms regulating the pathway of RAC activation by SOS1
through formation of the E3B1-EPS8-SOS complex are still poorly un-
derstood although they are essential for the control of lamellipodia
protrusion and cellular migration or invasion. E3B1 is certainly a cri-
tical limiting factor as it binds SOS1 as well as GRB2. It is also known
that p66SHC specifically activates RAC by reducing formation of the
SOS1-GRB2 complex (activating RAS) and increasing the formation of
the SOS1-EPS8-E3B1 complex that specifically targets RAC [112]. It
was also reported that phosphorylation of the C-terminal region of
hSOS1 on Y1196 is sufficient to elicit its RACGEF activity in response to
the activation of various receptor and non-receptor TKs, and contribute
to BCR-ABL-induced leukemogenesis [28].
3.4.3. C-terminal PR-mediated SOS autoinhibition
Although the main role for the PR domain seems to be the recruit-
ment of SOS to activated receptors via binding to the SH3 domain of
GRB2 [113,114], there is ample evidence suggesting an additional in-
hibitory role for this domain. On one side, constitutive membrane tar-
geting (using lipid tethers) of SOS proteins significantly strengthens
RAS activation in transfected cells [115]. On the other, truncated SOS
constructs lacking the C-terminal domain are able to bypass GRB2-
mediated membrane recruitment and act as potent RAS activators
[93,116], indicating that the C-terminal region of hSOS1 downregulates
the intrinsic RASGEF activity of this protein and its deletion leads to
enhanced RAS-signaling and transforming activity [93,94]. Consistent
with this notion, nonsense mutations causing premature stop codons
that abolish the C-terminal PR domain have been found in hyperplastic
syndromes such as HGF-1 [6,117,118] and are also known to promote
oncogenic transformation [116]. Furthermore, several cancer-asso-
ciated mutations detected in hSOS1 also elicit truncations in the C-
terminal region that may contribute to human cancer [100,119].
Taken together, the available data suggest that the PR domain ac-
counts not only for the recruitment of SOS to the plasma membrane but
also for modulation of its intrinsic RASGEF activity. Indeed, the first
two canonical GRB2 binding sites in the C-terminal region of hSOS1
have a critical role for this regulation [93]. The dual role of GRB2
(recruitment of SOS to the plasma membrane upon TKRs stimulation
and downregulation of the SOS RASGEF activity under basal condi-
tions) has relevant physiological implications, suggesting that the C-
terminal region of SOS has the ability to independently inhibit RAS
binding to SOS, probably by blocking the access of RAS to either the
allosteric or catalytic site of SOS [15] (Fig. 2B).
In any event, it is apparent that complete self-inhibition of SOS
requires allosteric inhibitory modes of both the N- and the C-terminal
regulatory modules, and that these N- and C-terminal inhibitory func-
tions are independent of each other (Fig. 2B). The multiple possibilities
available in theory for membrane interactions with a great variety of
distinct lipids or activated RTKs suggests the possible existence of
multiple, alternative regulatory mechanisms capable of releasing either
the N- and/or the C-terminal inhibitory conformations and the sub-
sequent allosteric activation of SOS in cells [15].
4. SOS GEFs in physiology
4.1. Functional specificity/redundancy and hierarchy of action
There is ample consensus indicating that the members of the SOS
family of GEFs are the most universal and functionally significant GEF
activators of the RAS GTPases [1,5,6,16]. Whereas SOS1 and SOS2 are
widely expressed in practically all cells, tissues and organs analyzed,
the pattern of expression of the two other main families of mammalian
RASGEFs (GRF1-2 and GRP1-4) is much more limited, with the GRFs
being preferentially expressed in the central nervous system and the
GRPs preferentially expressed in hematopoietic cell lineages
[1,4,5,16,91,120].
Despite the overall evidence supporting a dominant functional role
of the SOS GEFs over other GEFs with regards to the process of acti-
vation of RAS GTPases in metazoan cells, there are still many relevant
mechanistic questions to be clarified concerning the functional speci-
ficity or redundancy of the two SOS family members, or their hierarchy
of action on their many different, potential target GTPases. These
questions are difficult to address because they are concerned with two
co-expressed, highly homologous SOS1/2 isoforms with proven ability
to activate, at least in vitro, all members of the RAS family and some
RHO family members, particularly RAC1. These difficulties are further
compounded by the frequent co-expression, in many different cell
types, of both SOS1/2 isoforms together with other GEFs [121,122].
The phenotypic analysis of various animal models pertaining loss-
of-function or gain-of-function of SOS genes in flies, worms, zebrafish
and rodents along metazoan evolution, as well as studies of exogen-
ously expressed or mutagenized SOS molecules in different mammalian
cell lineages, have started to provide initial, relevant answers to many
of these general functional questions. All these studies firmly document
that the SOS1/2 GEFs play central, critical roles in the process of ac-
tivation of RAS GTPases in eukaryotic cells.
Regarding target specificity, there is extensive experimental evi-
dence, arising from a wide variety of cellular settings, documenting the
ability of the SOS GEFs to activate not only all canonical members of
the RAS subfamily (HRAS, NRAS and KRAS), but also the RAC1 mem-
bers of the RHO subfamily [28,66,74,123,124]. As previously
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mentioned, the capacity of the modular SOS proteins to act as GEFs for
both RAS and RAC proteins is based on their ability to differentially
interact with specific intracellular adaptor proteins such as GRB2 or
E3B1, respectively [1,5,6,13,66,74].
Regarding hierarchy of action, most reports support the functional
predominance of SOS1 over SOS2 in a majority of biological contexts
tested, with SOS2 playing secondary, complementary roles that are
more easily detected in experimental systems where SOS1 is absent
[23,25,26,28]. However, in some cases a functional predominance of
SOS2 over SOS1 has been reported, and even a hierarchical require-
ment for SOS2 regarding mutant RAS-driven transformation has also
been clearly shown. In particular, a hierarchical requirement for SOS2
regarding mutant RAS-driven transformation has been recently claimed
in view of the experimental evidence showing that RTK-SOS2-WT RAS
signaling, but not allosteric SOS2 activation, is a critical mediator of
PI3K signaling in the context of mutant RAS [125,126].
All in all, despite the considerable functional knowledge so far ac-
cumulated [1,4–6,66], we still do not know most of the specific me-
chanistic details accounting for the multilayered and multifaceted
regulatory circuits modulating the specific action(s) of SOS1 or SOS2 in
various cellular contexts as well as in different physiological and pa-
thological processes. Progress in this regard will not be easy but it is of
vital importance, especially now that the SOS GEFs have started to be
considered as valuable therapy targets for human developmental and/
or tumoral pathologies.
4.2. Role in organismal developmental
The critical role played by SOS GEFs in developmental processes as
well as in overall organismal survival and homeostasis is supported by
phenotypic analyses and observations in different animal models along
metazoan evolution, ranging from flies to mammals (Supplementary
Table 3). As previously mentioned, SOS was initially discovered as an
essential regulator/contributor/component of the neural development
pathway responsible for formation of the D. melanogaster compound eye
that are initiated by the Sevenless RTK [7,11,12]. Interestingly, those
early studies showed also that direct mutagenic inactivation of this
locus by irradiation or treatment with ethylmethanesulfonate gave rise
to recessive lethal SOS null mutants, demonstrating its essential role not
only for neuronal development but also for larval survival [7,11,12].
In the nematode C. elegans, the previously known let-341 gene has
also been shown to encode SOS1 and to play a critical role in the
process of vulval development initiated by the upstream let-23 RTK in
this worm [9]. Regarding organismal development, RNAi-mediated si-
lencing of SOS1 caused low penetrance lethality (8%) and the surviving
animals escaping early larval lethality displayed slow growth and
scrawny body morphology [9]. Interestingly, a gain-of-function SOS1
mutation mapping to the DH domain was later found and shown to
suppress the defective vulvar phenotype in specimens harboring let-23
(EGFR) loss-of-function mutations, thus highlighting the known auto-
inhibitory role exerted by this domain over the overall GEF activity of
SOS1 [127].
The process of meiotic maturation of stage II oocytes of the am-
phibian Xenopus has also proven to be a useful system to analyze
functional activities of signaling molecules participating in RTK-RAS
signaling pathways [128,129]. Interestingly, microinjection of a pep-
tide coding for the SOS1 PH domain was shown to trigger Germinal
Vesicle Breakdown in this system suggesting that, unlike PH domains
from other cellular proteins, isolated SOS1 PH domains retain func-
tional specificity and the ability to productively interact with RAS-
mediated signaling pathways participating in the GVBD process [130].
During zebrafish development, it has been shown that a signaling
complex containing Nostrin along with SOS1 and RAC1 is necessary for
proper vascular development during developmental angiogenesis
[131]. Furthermore, consistent with GWAS studies of chronic kidney
disease patients that identified an association of SOS2 with the disease,
knock-down of SOS2 in zebrafish embryos was also shown to cause
abnormalities of embryonic kidney development (involving changes of
glomerular gene expression and renal tubule morphology) [132].
Regarding loss-of-function mammalian animal models, the initial
analysis of constitutive knockout (KO) murine strains for SOS1 gene
showed that SOS1 is essential for intrauterine development, with con-
stitutive-null-animals dying during mid-gestation due to defects of the
embryos [22] and/or placental development [20]. In contrast, adult
SOS2-constitutive-KO mice were perfectly viable and fertile, with no
evident phenotypic abnormalities [21]. Interestingly, the SOS1 null
mutations found in SOS1-constitutive-KO mice are the only embryonic
lethal mutations identified among all different RASGEFs in mammals,
suggesting a dominant role of SOS1 over SOS2 and the rest of mam-
malian RASGEFs regarding embryonic development.
The difficulties initially imposed on SOS1 functional analysis in
adult animals by the embryonic lethality of the homozygous SOS1-KO
null alleles were bypassed by using a conditional, floxed SOS1-null al-
lele generated in the Samelson’s NCI lab to characterize the functional
significance of SOS genes during thymocyte development [24] using a
Cre recombinases expressed under the control of T-cell specific pro-
moters. Using Samelson´s Sos1fl/fl mice, our group generated tamox-
ifen-inducible SOS1-KO mice expressing the SOS1 null mutation
throughout the adult body upon TAM administration [23], and sub-
sequent cross-breeding with constitutive SOS2-KO mice colony [21]
allowed generation of comparable sets of WT, SOS1-KO, SOS2-KO and
SOS1/2-DKO mice sharing the same genetic background, thus facil-
itating phenotypic comparisons and allowing functional conclusions
regarding the SOS1/2 GEFs in a variety of biological contexts. Inter-
estingly, whereas single SOS1-KO and SOS2-KO mice are perfectly vi-
able, the SOS1/2-DKO mice died precipitously, suggesting some degree
of functional redundancy for SOS1 and SOS2 with regards to adult or-
ganismal homeostasis and survival [23]. The availability of this in-
ducible, loss-of-function system in mice has opened avenues to char-
acterize specific function of SOS1 and/or SOS2 in a variety of biological
contexts including different cell lineages as well as various physiolo-
gical and pathological or tumoral processes. Furthermore, some recent
reports have also described the use of modern CRISPR/Cas9 technolo-
gies to generate SOS1-devoid or SOS2-devoid [125,126,133–135]
tumor cell lines that are instrumental for characterization of specific
contributions of SOS1/2 to different cancer signaling pathways or for
the search of new SOS agonists and antagonists.
Mouse models involving gain-of-function have also been instru-
mental for functional characterization of SOS gene products. Thus,
transgenic mice developing upon expression of a dominant form of SOS
(K5-SOS-F) in basal keratinocytes [136] have been useful to char-
acterize EGFR- and SOS1-dependent signaling pathways in skin tumors
[137,138]. Adult mice heterozygous for a dominant SOS1E846K muta-
tion in the CDC25H domain have also been used as a valid model for NS
studies [139]. On the other hand, no animal models exhibiting SOS2
gain-of-function mutations have yet been reported in the scientific lit-
erature.
4.3. Roles in specific cell lineages
The functional specificity or redundancy of the SOS1/2 GEFs has
also been analyzed in a wide range of non-tumor and tumor cell lines
cells using loss-of-function or gain-of-function approaches. This section
summarizes available reported data on functional roles played by
SOS1/2 under physiological conditions in a variety of specific cell
lineages and tissues (Supplementary Table 4).
4.3.1. SOS1/2 Role in progenitor and embryonic stem cells
Analysis of the two initial, independently developed, constitutive
SOS1-KO mouse strains reported in the literature, indicated that SOS1 is
essential for intrauterine development, with homozygous null animals
dying in mid-gestation [20,22]. Whereas the earlier report [22]
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attributed the deaths of the mice to yolk sac and embryonic heart de-
fects, detailed analysis of the KO animals generated by Qian et al. de-
monstrated that their embryonic lethality is due to impaired develop-
ment of the trophoblastic and spongio-trophoblastic lineages of the
placental labyrinth [20]. Consistent with this, more recent studies in-
volving the use of SOS1-/- mESCs derived from Wang’s KO strain con-
firmed that SOS1-GRB2 interaction is essential to control embryonal
stem cell fate, driving the embryonic stem cells toward the primitive
endoderm, an essential, clearly extraembryonic lineage [67]. Interest-
ingly, whereas SOS2-KO mice do not show any alteration of intrauterine
development [20,21], SOS2 silencing in SOS1-/- mESCs resulted in in-
hibited priming and differentiation of these cells to primitive en-
doderm, suggesting the possibility of some partially redundant func-
tional role of SOS2 regarding these developmental processes [67].
4.3.2. SOS1/2 function(s) in mesenchymal lineages
Regarding fibroblasts, the main stromal cell lineage, analysis of
primary MEFs cultures derived from the initially generated SOS1-KO
mouse strains documented the critical role of SOS1 in growth factor
signaling initiated by upstream RTKs like the EGFR [20,22]. Further
analysis of SOS1-KO fibroblasts, which retain normal SOS2 expression,
showed that SOS1-/- cells (unlike SOS1+/- cells) are resistant to trans-
formation by upstream tyrosine kinase oncogenes and suggested that
SOS1 participates in short-term and long-term RAS-ERK signaling
whereas SOS2-dependent signals are predominantly short-term [20].
More recently, detailed comparisons among WT, SOS1-KO, SOS2-KO an
SOS1/2-DKO primary MEFs sharing the same genetic background have
demonstrated a critical, dominant role of SOS1 over SOS2 in control of
essential critical cellular processes including proliferation, migration,
inflammation or maintenance of intracellular redox homeostasis
[23,25,27]. Interestingly, whereas single SOS2-KO fibroblast cells did
not show measurable defects in any of the above mentioned cellular
processes, the defective phenotypes of DKO cells were routinely
stronger than in single SOS1-KO cells, suggesting some partial ability of
SOS2 to functionally contribute to those cellular processes under
normal conditions, or at least in the absence of SOS1 [25,26].
The critical functional role played by SOS1 (but not SOS2) in adi-
pocytic cell lineages was initially substantiated in studies that identified
(for the first time) a negative regulatory mechanism acting on SOS1
GEF activity. Interestingly, after insulin stimulation of 3T3L1 adipo-
cytes, and once maximum levels of RAS•GTP are reached, hormone
treatment causes also marked hyperphosphorylation of SOS1 and sub-
sequent decrease (by 50%) of cellular GRB2-SOS1 complexes. This in-
dicates that this SOS1-dependent negative feedback mechanism is an
essential component of the physiological process of desensitization after
insulin hormone stimulation of those cells [140]. The functional in-
volvement of SOS1 in modulation of adipocytic differentiation is further
supported by a report showing that the endocytic DAB2 adaptor protein
determines the commitment of pre-adipocyte cell populations through a
mechanism involving the disassembly of GRB2-SOS1 complexes asso-
ciated with clathrin-coated vesicles in those pre-adipocytic cell types
[141].
Regarding muscle cell lineages, SOS1 was initially shown to be an
essential component of a signaling complex (SHC-GRB2-SOS-EGFR)
mediating hydrogen peroxide-induced activation of the RAS-ERK
pathway in mouse vascular smooth muscle cells [142]. In the same cell
type, SOS1 has also been shown to modulate RAC1-dependent processes
of cellular migration involving the formation of podosomes and dorsal
ruffles [143]. Furthermore, SOS1 was also shown to participate in the
process of laminin-induced activation of RAC1 in mouse cell types in-
volved in skeletal muscle contraction [144].
Finally, regarding bone-related cell lineages, SOS1-mediated signals
have been shown to participate in osteoblast differentiation [145] and
upregulated SOS1 mRNA levels have been reported in rat osteoblasts
exposed to spaceflight as compared to those in the ground [146].
4.3.3. Sos1/2 function in hematological lineages
The functional role(s) of SOS1/2 GEFs in T cell development and
signaling has been studied and characterized in detail. Initial studies
documented the critical role of SOS1 in early T-cell development,
during DN2/DN3 transition, and demonstrated that SOS1 is required
for preTCR- but not TCR-stimulated developmental signals [24]. In
particular, SOS1 deletion led to a partial block at the DN-to-DP tran-
sition, whereas positive and negative selection performed under TCR-
mediated strong stimulatory conditions, remained intact upon SOS1
depletion.
Further functional analysis of other RASGEFs during thymocyte
development has shown that, although SOS1 is the dominant RASGEF
at pre-TCR stages, GRP1 becomes more functionally prevalent at later
stages of thymocyte maturation [23,90,147,148]. This functional in-
terplay/redundancy between SOS1 and GRP1 during positive and ne-
gative selection steps may constitute a safeguard, adaptive mechanism
ensuring appropriate responses to possible variations of physiological
environmental conditions.
Although SOS1 is clearly the leading physiological SOS player re-
garding pre-TCR selection steps, a partial, limited contribution of SOS2
to these processes cannot be excluded based on the observation of an
almost complete disappearance of the thymus and a dramatic reduction
of thymocyte counts in SOS1/2-DKO animals as compared to single-KO
mice. Furthermore, absolute counts of mature B and T cells in spleen
and peripheral blood (PB) were unchanged in single-KO mutants, while
significantly reduced in SOS1/2-DKO mice [23].
Regarding RTK-RAS-dependent signaling in T cells, the study of
murine strains undergoing Lck-Cre or CD4-Cre-driven depletion of
floxed SOS1 alleles has confirmed that SOS1 is essential for ERK acti-
vation downstream of the pre-TCR at the DN3 stage, but becomes
progressively less important as T cells maturation proceeds. Consistent
with separate observations in Jurkat and peripheral T cells, analysis of
SOS1/2-DKO mice shows that TCR-mediated ERK activation in per-
ipheral CD4+ T cells is independent of SOS1 and SOS2
[23,24,90,149–151]. In contrast, SOS1/2-DKO CD4+ T cells show
impaired IL-2-mediated ERK activation as well as activation of PI3K/
AKT signaling associated to subsequent impairment in T-cell migration
upon TCR and IL-2 stimulation [149,152], an observation also seen in
Jurkat and primary CD4+ T cells [153–155]. SOS1 also mediates am-
plification of TCR-induced ERK phosphorylation upon IL-7 and IL-15-
induced priming of human T cells isolated from PB [156]. Interestingly,
in primary human T cells, RASGRP1 regulates transient ERK activation
but sustained ERK phosphorylation depends on both RASGRP1 and SOS
[157] and SOS1 depletion results in a loss of adhesion capacity that has
been directly related to reduced activity of RAC1 and RHOA and de-
creased integrin-mediated signaling [158]. Finally, SOS1 acts as a
scaffold to nucleate oligomerization of the T cell adaptor protein LAT
(Linker for Activation of T cells) in vivo in T cells but, interestingly, the
GEF activity of SOS1 and the SOS1-dependent oligomerization of LAT
are separable functions in vivo [151].
Comparatively less is known about functional role(s) of SOS1 and
SOS2 in B lymphocytes. Analysis of SOS-KO mice showed reduced
percentage of total bone marrow (BM) precursors in single-KO animals,
but a dramatic depletion of B-cell progenitors was specifically detected
in SOS1/2-DKO mice. Likewise, absolute counts of mature B cells in
spleen and PB were almost unchanged in single-KO mutants but very
significantly reduced in SOS1/2-DKO mice, suggesting functional re-
dundancy between SOS1 and SOS2 for development and maturation of
B lymphocytes in mice [23].
Regarding participation in B-cell signaling pathways, early studies
indicated that ERK phosphorylation upon BCR stimulation is mainly
regulated by RASGRP1/3, rather than by SOS in DT40 B cells [90,159].
However, more recent studies have reported that both SOS1 and SOS2
downregulation leads to reduced RAS- and p38-mediated signaling in
different lines of B cells after BCR or EGFR stimulation [65,154,155].
Consistently, SOS1 GEF over-activation resulting from transfection of
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SOS1cat constructs, results in increased RAS activation upon EGFR
stimulation in DT40 and RAJI B cells [90].
Regarding inflammation-related cell populations such as macro-
phages, it has been shown that LPS induces lysosomal degradation of
SOS1 (and subsequent inhibition of ERK activation) in a DOK3-depen-
dent manner in BM-derived macrophages (BMM) [160]. SOS1 has also
been shown to regulate BMM podosome assembly and macrophage
invasive capacity [161]. More recently, a study using murine peritoneal
macrophages and the P388D1 mouse macrophage cell line has de-
monstrated that weak CD40-mediated signal in macrophages activates
NRAS via SOS1/2 and regulates ERK activation and IL-10 production
[162]. Finally, skin wound-repair in combined SOS1/2-DKO mice
showed markedly reduced migration of macrophages to the injury site
[26]. SOS1/2 signaling plays a key role in determining the respon-
siveness of neutrophils in regions of inflammation. Thus, studies using
SOS1/2-DKO mice have shown that the SOS GEFs play significant roles
in regulation of pro-inflammatory responses, in primed, but not basal
neutrophils, upon GM-CSF1 and TNFα stimulation [27,163]. Strikingly,
single SOS1 deletion has no effect on neutrophil recruitment upon skin
injury stimulation, whereas SOS2 absence increases the capability of
neutrophils to migrate to the inflammatory site. However, combined
deletion of SOS1 and SOS2 results in almost complete blockade of the
migration of neutrophils (and also macrophages) to the site of injury
[26]. In NK cells, SOS1 appears to be essential to establish NKG2D-
mediated immunological synapse [164]. On the other hand, SOS2 has
been proposed to participate in the activation of basophils upon IgE-
stimulation [165].
Although no significant changes of the levels of early erythroid
precursors were observed in SOS1/2-deficient mice [23], treatment of
primary human CD34+ cells with a SOS-SH3 inhibitor showed that
SOS-mediated signaling is essential for EPO-mediated erythroid differ-
entiation by reducing MASL-1 expression [166]. In fact, SOS1 appears
as an enriched gene during BM-derived mesenchymal stromal cells-
regulated proliferation and differentiation of CD34+ erythroid cells
[167]. Consistent with this, SOS1 gain-of-functions occurring in NS
patients cause an increase in the number and survival of CD34+ cells
[168]. Direct involvement/participation of SOS1 and SOS2 protein
complexes in the process of EPO-induced ERK activation in human F-
36P erythroid cells [169] or mouse Ba/F3 cells [170] has also been
reported.
Finally, the functional relevance of SOS proteins acting as RACGEFs
in platelets has been documented by the demonstration that protein-
protein interaction between SOS and PI3K-SYK is crucial for fibrinogen-
induced lamellipodia and filopodia formation in this particular cell type
[171]. Moreover, a recent study have demonstrated that NSC-658497
SOS1 inhibition significantly inhibited GPVI-mediated platelet adhe-
sion, dense granule secretion and integrin activation [172].
Consistent with our observations indicating that the embryonic
lethality of SOS1-KO mice is due to defective development of the tro-
phoblast layers of the placental labyrinth [20], recent reports have
documented substantial roles of SOS1 in endothelial and vascular de-
velopment [173,174]. Indeed, the critical role of SOS GEFs in angio-
genesis is also supported by in vivo and ex vivo assays in SOS1/2-DKO
mice that showed significantly reduced levels of the steady-state density
of dermis blood vessels as well as markedly reduced capacity of for-
mation of new blood vessels in the skin and in aortic ring explants from
SOS1/2-DKO mice [26]. Interestingly, independent studies of different
endothelial cell systems from mouse, human or zebrafish origin have
identified SOS1 as an essential mediator of RAC1 activation by different
agonists and subsequent for induction of specific responses in those cell
types [131,175,176].
4.3.4. SOS1/2 functional role(s) in epithelial cells
The critical functional role played by SOS GEFs in epithelial cell
lineages was evident from their initial discovery in primitive metazoan
developmental systems dependent upon EGFR-like initiated signals
such as those leading to formation of the compound eye in flies
[7,11,12] or the vulval organs in nematodes [9,127]. Consistent with
this, an initial report characterizing mechanisms of EGFR involvement
in mouse skin development demonstrated that expression of a dominant
SOS transgene caused significant hyperproliferation of the basal kera-
tinocyte compartment leading to hyperplasia and papilloma formation
[136]. Conversely, analysis of the skin of SOS KO mice has shown that
single SOS1 depletion (but not SOS2 depletion) significantly reduced
keratinocyte proliferation in the epidermis in vivo, but this defect was
significantly worsened when both SOS1 and SOS2 were concomitantly
absent in DKO mice, suggesting a predominant role of SOS1 (and a
possible secondary adjuvant role of SOS2) in control of keratinocyte
proliferation [26]. On the other hand, studies on normal foreskin
human keratinocytes have shown that SOS1 appears to be totally dis-
pensable for the process of E-cadherin-induced RAC1 activation during
the establishment of cadherin junctions among these cells in the skin
[177].
The role of SOS1 acting downstream of the EGFR to activate RAS-
ERK proliferative signaling in epithelial cell lineages has also been
demonstrated in epithelial cells of the intestine where EGFR-SOS1-RAS
growth signals are opposed and dampened through the action of an-
other GEF, GRP1, to modulate normal homeostasis of the intestinal
epithelium [178]. Likewise, FGF2-mediated dampening of SOS1-de-
rived (proliferative) signals appears to be an important mechanism in
processes of repair of intestinal epithelial damage occurring in various
gut pathologies [179].
The importance of the EGFR-SOS1 signaling axis is further demon-
strated by experiments showing that the EGFR uses SOS1 to drive
constitutive activation of NFκB in various epithelial cancer cells [180]
or that SOS1-mediated signaling seems also essential during epithelial-
to-mesenchymal transition in tubular renal cells [181].
Regarding lung epithelia, shRNA-mediated silencing of SOS1 in
human bronchial epithelial cells has demonstrated the critical role of
SOS1 for proper cell migration and tight junction formation during lung
airway morphogenesis. Introduction of a SOS1 gain-of-function mutant
(N233Y) in immortalized tracheobronchial epithelial cells results in
increased RAS-ERK signaling, cell proliferation, and colony and tumor
formation, further supporting the relevant role of SOS1 in RAS-ERK
activation in lung epithelia [182]. In contrast, cyclic stretch-mediated
ERK activation in alveolar epithelial cells appears to be independent of
SOS-mediated signals in this particular cell type [183].
4.3.5. SOS functional role(s) in neural cell lineages
The functional involvement of SOS GEFs in neural cell lineages was
already evident from its initial discovery as an essential regulator of the
development of the neuronal R7 photoreceptor cells in the Drosophila
compound eye [12,184]. Further studies in Drosophila also demon-
strated that SOS signaling, involving specifically its RAC1 GEF activity,
is essential for axon guidance to interpret midline repulsion clues, that
regulating which axons cross the midline [185–187]. SOS has also been
identified in Drosophila glial cell lineages as an essential upstream RAC1
GEF activator required for proper glial responses to axonal injury,
during post-injury responses involving glial engulfment of axonal debris
in this fly nervous system [124]. Consistently, the introduction of
magnetic nanoparticles carrying bound SOScat domain has been re-
cently proposed as a potential therapy approach in Parkinson’s disease,
to guide neurite regeneration in human dopaminergic neurons [188].
Multiple reports have also described the expression and functional
interactions of SOS GEFs with other signaling molecules and binding
partners in a large variety of neuronal cell types. For example, in
Schwann cells, neuregulin ligands (members of the EGF family of li-
gands) have been reported to induce rapid association of SOS with the
HER2/HER3 receptor complex [189]. Likewise, analysis of murine
brain extracts, as well as isolated neurons and nerve terminals, have
identified the endocytic protein intersectin as a major binding partner
of SOS1 [190]. Studies using chicken embryonic tissues and cell
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cultures have also shown that PKCε-dependent HRAS activation and
subsequent regulation of neuronal differentiation and highly specia-
lized functions encompasses the recruitment the SOS1 (and neurofi-
bromin) in the lipid rafts of embryonic neurons [191]. Studies on
Huntington´s disease using transfected neuro2A cells have also shown
that mutant huntingtin exhibits higher affinity than GAB1 for, and re-
places it, in the GRB2-SOS-GAB1 complexes that are normally found in
healthy neural cells as essential mediators of sustained RAS activation
[192].
Although the SOS1/2 GEFs appear to be ubiquitously expressed,
there are quantitative differences of their expression in different cel-
lular and subcellular locations, suggesting functional specificity of one
of the other SOS isoform at the spatial or temporal level, or under
different neural contexts. For example, very distinct intensities of ex-
pression of SOS1 and SOS2 are detected in different layers and cell-
subpopulations of the retina in rats and humans [193]. Furthermore, it
has also been reported that SOS1, but not SOS2, is found in the post-
synaptic density fraction of the rat forebrain, suggesting a dominant
role of SOS1 in the regulation of RAS-ERK signals participating in sy-
naptic transmission and its regulation at post-synaptic sites [194].
Likewise, SOS2 has been shown to be dispensable for NMDA-induced
ERK activation and LTP induction in cortical neurons, implying that
SOS1 is the main regulator of this neuronal functions [195]. In contrast,
SOS2 appears significantly upregulated in a population of neurons lo-
cated at the subgranular layer of the hippocampus after traumatic brain
injury, suggesting a potential role of SOS2 at least upon brain insult
[196]. On the other hand, SOS1 and SOS2 exhibit functional re-
dundancy in the process of RIT-mediated differentiation of neuronal
pheochromocytoma PC6 cells that involves formation of TRKA-SHC-
SOS complexes [197]. Interestingly, in PC12 cells, SOS1 and SOS2 are
both crucial for RAS activation upon NGF-stimulation, but they seem to
be largely dispensable for RAC activation under the same conditions
[198].
5. SOS GEFs in pathology
5.1. Gain-of-function mutations in pathology
Classical studies along the last 30 years have demonstrated that the
activation of RAS proteins by means of point mutations causes a variety
of pathological alterations including multiple types of tumors (sporadic
mutations) as well as inherited developmental syndromes
(“RASopathies”) (germline mutations). In addition, experimental evi-
dence has recently suggested that other potential, alternative mechan-
isms of RAS activation, including hyperactivation of cellular GEFs or
deregulation of other components of RAS signaling pathways, may also
lead to development of physiological or pathological alterations
[2,5,6,199].
In particular, an ample collection of recent reports on SOS gene
products have started to identify a variety of molecular mechanisms
including (i) gene amplifications, (ii) gain-of-function mutations, or (iii)
overexpression of SOS gene products that result in GEF hyperactivation
and subsequent hyperactivation of RAS signaling in different biological
contexts. Importantly, many of these molecular alterations have been
found In association with various pathologies including RASopathies
(SOS germline alterations), cancer (somatic alterations) or other non-
cancer pathologies [5,6,82,200]. It is precisely this specific association
of SOS1/2 molecular alterations with specific tumoral and non-tumoral
pathologies which underlies current academic and industry efforts at
determining whether these molecular alterations of SOS GEFs may
constitute meaningful biochemical biomarkers or therapeutic targets.
5.2. SOS in RASopathies and developmental syndromes
The RASopathies encompass a defined group of hereditary devel-
opmental syndromes that are caused by germline mutations affecting
genes encoding components or regulators of the RAS-ERK pathway.
They represent one of the most prevalent groups of human malforma-
tion syndromes and include a variety of different clinical syndrome
entities including neurofibromatosis (NF1), Costello syndrome (CS),
Legius (LGSS), Leopard (LPRD), cardiofaciocutaneous syndrome (CFC),
Noonan (NS) and other NS-like disorders. As the common underlying
biochemical phenotype shared by all the RASopathies is hyper-activa-
tion of the RAS-ERK pathway, it is not uncommon to observe over-
lapping phenotypic features among these syndromes including, among
others, facial dysmorphology, cardiovascular disease, and muscu-
loskeletal anomalies or mental disorders [31,81,82,200]. These patho-
genetic mechanisms may include functional alteration of RAS-GTPases,
RASGAPs, RASGEFs, kinases, scaffolding or adaptor proteins, ubiquitin
ligases, phosphatases, and pathway inhibitors [82,200,201]. Re-
markably, among all mammalian RASGEFs, only SOS1 and SOS2 have
been found altered in RASopathies, further supporting the predominant
functional role of the SOS1/2 GEFs over other RASGEFs in mammalian
cells.
5.2.1. SOS1/2 in Noonan syndrome
The most common RASopathy is NS, an autosomal dominant con-
dition whose features may include distinctive facial appearance, short
stature, broad or webbed neck, congenital heart defects, bleeding pro-
blems, skeletal malformations, as well as physical and neurodevelop-
mental delays and cognitive deficits [31,82,202,203].
NS is genetically heterogeneous and may be caused by a mutation in
any of several genes coding for different components of RAS signaling
pathways and can be classified into subtypes (NS1 through NS12)
(OMIM database, https://omim.org/phenotypicSeries/PS163950) ac-
cording to the responsible gene (https://rarediseases.info.nih.gov/
diseases/10955/noonan-syndrome). PTPN11 is responsible for NS1
and is the most frequently mutated gene in NS (~50% of cases). SOS1 is
the second most mutated gene (~16.5% of familiar and sporadic cases)
and its mutational activation is the cause of the NS4 subtype. More than
60 NS-related mutations leading to various levels of constitutive hy-
peractivation of SOS1 have been identified in different domains of the
hSOS1 gene. Most of them are missense mutations, although small de-
letions, small insertions and small indels have been also reported
[31,204] (Fig. 3). Moreover, specific NS Ras mutants (I24N, T50I,
V152G and D153V) have been reported to deregulate allosteric SOS
autoactivation [205].
The phenotype of NS4 caused by SOS1 mutations lies within the NS
spectrum although a certain prevalence of cardiac defects and ecto-
dermal abnormalities has been were initially noted [31,206].
Consistent with the overlapping phenotypic features exhibited by
different RASopathies, there are also reports of rare SOS1 mutations
detected in patients with related RASopathies, such as CS/CFC syn-
drome [207] or NS-like/multiple giant cell lesion syndrome [208].
In addition, some NS patients bearing SOS1 mutations have also
been reported to develop various types of tumors including, paraspinal
tumors [209], pediatric colorectal cancer [210], embryonic rhabdo-
myosarcoma, Sertoli cells tumor or granular skin tumors [211,212],
melanoma [201] or acute lymphoblastic leukemia [213], thus high-
lighting the predisposition and interplay existing between these de-
velopmental syndromes and cancer.
Although the initial screenings did not detect mutations in SOS2
gene in NS patients [202], more recent studies have detected the pre-
sence of missense activating mutations in 7 specific residues of the DH
domain of SOS2 that are responsible for maintaining this GEF in an
autoinhibited conformation and appear to favor predisposition to
lymphatic complications (Fig. 3) [30,82,214,215] in a small percentage
of NS subjects with marked ectodermal involvement, thus defining the
NS9 subtype of this syndrome (https://omim.org/phenotypicSeries/
PS163950).
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5.2.2. SOS1/2 in hereditary gingival fibromatosis (HGF-1) and related
syndromes
HGF is a rare, autosomal dominant condition characterized by be-
nign, uncontrolled gingival overgrowth. Large-scale genetic analyses of
affected individuals identified a causal mutation involving a single
cytosine insertion in exon 21 of the SOS1 gene (3248_3249insC) in-
troducing a frameshift and creating a premature stop codon that lead to
a shortened SOS1 protein having a 22 amino-acid missense addition at
the C-terminus and missing almost completely the C-terminal PR do-
main. The loss of the PR region results in loss of autoinhibition and
constitutive activation of SOS1 and subsequent RAS signals that provide
a likely pathogenic mechanism for this malformation [118,216]. It is
unclear why the overgrowth of tissue is seen only in the gums, but
histological analysis identified increased fibroblast numbers (over 30%)
in the gingiva of SOS1 HGF patients than in normal counterparts.
Furthermore, cultures of HGF fibroblasts showed significantly higher
rates of proliferation and levels of RAS-ERK activation than in normal
human fibroblasts [117]. Interestingly, miR335-3b, which is capable of
directly targeting SOS1 gene, has shown antifibrotic potential in assays
using normal human gingival fibroblasts [63]. Nevertheless, HGF dis-
plays genetic heterogeneity, and mutations in genes other than SOS1
are also likely to be involved, as suggested by reports analyzing dif-
ferent cohorts of familial and non-familial gingival overgrowth patients
[217,218].
SOS1 mutations have also been found in other syndromes clinically
related to HGF such as pure mucosal neuroma syndrome, an autosomal
dominant neurocutaneous disorder where different frameshift muta-
tions affecting exon 20 of the C-terminal portion of SOS1 (c.3266dup,
c,3248dup and c.3254dup) as well as a heterozygous SOS1 exon 20
mutation (c.3255_3265del) have been recently described, thus defining
a clinical phenotype distinct from MENS2B and characterized by no-
table gingival hypertrophy associated to arytenoid neuromas which are
a recognized feature of the SOS1 mutations [219,220]. Likewise, tran-
scriptional analysis of fibrous epulis samples, a type of hyperplastic
lesions with tumor-like appearance predominantly located in the gin-
gival or alveolar mucosa, show significantly elevated levels of SOS1
expression [221].
Interestingly, in hereditary hyperplastic gingivitis, an autosomal
recessive condition found predominantly in farmed silver foxes that is
analogous to the HGF occurring in humans, SOS2, but not SOS1, has
been found to be upregulated and proposed as a candidate gene for this
disease [222].
5.3. SOS in sporadic cancers
The 3 canonical RAS family members (KRAS, NRAS and HRAS), as
well as upstream RTKs such as the EGFR or downstream cytoplasmic
kinases like RAF and PI3K, account for the majority of cancer driver
genes identified during the past 3 decades as undergoing activating
somatic mutations in a wide variety of human tumors types sharing the
Fig. 3. SOS mutations in RASopathies.
Schematic representation of mutations affecting the indicated domains of hSOS1 or hSOS2 that have been reported in different inherited RASopathies including NS4:
SOS1-related Noonan syndrome; NS9: SOS2-related Noonan syndrome; HGF-1: Hereditary gingival fibromatosis; CS: Costello syndrome; LPRD: Leopard syndrome.
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dysregulation of RTK-RAS-ERK or RTK-RAS-PI3K signaling pathways as
a common mechanistic feature [32,33,223,224]. However, as more and
more tumor samples have been profiled in recent years, many new
mutations (unnoticed in the earlier screens) affecting genes coding for
other components of RAS-ERK pathways have now been reproducibly
found (in smaller proportions) in some specific tumor types, indicating
that they have real pathophysiological relevance for the development of
such tumors [32,33,223]. Indeed, this has been the case for many SOS1
mutations that were initially found as germline mutations in RASo-
pathies [31,82,225] and have been more recently reported as somatic
mutations in different sporadic tumor types.
Earlier genomic screenings of different tumor types did not report
any SOS gene alterations [226–229], and other studies started identi-
fied recurrent SOS1 gene alterations in germline RASopathies
[31,82,225]. However, more recent studies have started to uncover
SOS1 gene alterations as rare but reproducibly present in many
sporadic tumors including, in particular, lung adenocarcinoma (LUAD),
uterine corpus endometrial carcinoma (UCEC), urothelial bladder
cancer (BLCA), lung squamous cell carcinoma (LUSC), liver hepato-
cellular carcinoma (LIHC), acute myeloid leukemia (AML), lower grade
glioma (LGG) and cutaneous melanoma (SKMC) [32,33,37,230]. The
list of SOS1 gene alterations found in specific association with different
human tumor types includes some scarce amplifications resulting either
from copy number variations or upregulated expression, as well as more
frequent somatic mutations, particularly base substitutions, causing
amino acid changes or premature terminations in specific functional
domains of SOS1 that have been recognized as gain-of-function genetic
mutations capable of hyperactivating SOS1, and subsequently RAS-ERK
signaling, in those tumors [33] (Fig. 4).
An updated catalog of SOS1 somatic mutations detected in many
different tumor types can be found in the COSMIC database (https://
cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SOS1#genome-
browser), where about one third of tumor samples tested are reported
to present mutations in SOS1 including missense substitutions (~39%)
followed by synonymous substitutions (~7%) and nonsense, truncating
substitutions (~2.5%). The most frequent substitution found is C>T
(~23%) although, frameshift insertions and deletions in hSOS1 have
been also detected with much lower frequencies (< 2%).
It is also relevant to mention that, except for endometrial and LUAD
tumors, most SOS1 somatic mutations reported in different cancer types
are not currently classified as canonical cancer driver genes according
to present criteria and standards, based mostly on frequency of detec-
tion (https://www.intogen.org/search?gene=SOS1). However, given
the central position and regulatory role played by SOS1 GEF in RAS
signaling pathways [33,223], these gain-of-function mutations are
likely to be significant components of the pathophysiological mechan-
isms driving development or maintenance of those tumors, and this has
been confirmed by many recent reports (see below). The consideration
of these SOS1 mutations as potentially oncogenic alterations is sup-
ported by the initial discovery of SOS mutations as the driving cause in
pathological conditions like NS and HGF-1 [30,31,117]. In addition,
this notion is further reinforced since the same recurrent functional
mutations have also been more recently identified in small percentage
of otherwise RAS-pathway driver-negative LUAD and UCEC tumors
(thus labeled as “non BRAF-non RAS” (NBNR) and “non-EGFR” tumors)
[32,33]. These observations underscore the notion that low-frequency
mutations of components of RAS signaling pathways that might
otherwise have gone statistically unnoticed in the past (such as the
SOS1 gain-of-function mutations mentioned here), can be significantly
relevant for tumor development based on their capacity to hyper-
activate RAS signaling in those tumors.
Many recent reports in the scientific literature document the various
genetic alterations (including somatic mutation, amplification or dif-
ferential expression) undergone by SOS1 genes in different tumor types.
Regarding somatic mutations, although early studies found SOS1 mu-
tations only very rarely in screenings of primary tumors [230,231] or
cohorts of specific tumor types [232,233], more recent reports have
started to document the specific association of SOS1 mutations with a
number of different cancer types, including LUAD otherwise devoid of
mutations in RTKs, RAS or RAF genes [32,182], NBNR thyroid carci-
nomas [234], mucosal neuromas without MEN2B-associated RET mu-
tations [220], melanomas devoid of NRAS or BRAF mutations [201]. A
recent review of genomic data from 9125 tumors profiled in the TCGA
database has confirmed the detection of rare, potentially oncogenic
SOS1 mutations identifying recurrent (hotspot) mutations (A90V/T;
N233Y/S) and other activating SOS1 mutations (M269I/V; G434R;
R552S/K/G/M; E846K) in 1% of LUAD and 1% of UCEC independent of
subtype, as well as in lower percentages of several other cancer types
including BLCA, LUSC, LIHC, AML, LGG and SKMC [33] (Fig. 4).
Rare polymorphic SOS1 variants have also been found in patients
with AML including two SOS1 (F494L and I610T) variants which were
heterozygously found in SOS1 exon 11 [235].
The amount of available cellular SOS1 is also relevant for tumor
development. It has been shown that the stability of SOS1-EPS8-E3B1
complex is critical for the metastatic ability of ovarian carcinoma cells
as shown by the observation that deficiency of at least one of the
members of this complex correlates directly with the loss of metastatic
capacity of ovarian tumors [36,236]. Genomic alterations involving
amplification of SOS1 gene have also been reported in specific tumor
types. Thus, early Northern and WB studies identified SOS1 over-
expression in different tumor cell lines originated from renal, bladder or
prostate, carcinomas [57,237–239]. More recently, significant copy
number variations of SOS1 have been detected in isolated tumor cells
and extracellular DNA from a cohort of LUAD patients [240] and
comparative genomic hybridization has also identified a large ampli-
fication (> 15 copies) of the hSOS1 gene in a patient with high-grade
glioma that was negative for BRAF mutations [35].
Several other reports underscore the diagnostic or prognostic value
of SOS1 gene alterations in different tumor types, further supporting the
relevance and pathophysiological role of SOS1 alterations in cancer. For
example, SOS1 appears to be differentially expressed in breast tumors
from African-Americans (AA) as compared with Caucasian women
[241], and this differential expression is especially marked in "quad-
ruple negative" (QNBC) breast cancers of AA women [242], suggesting
a possible contribution of this overexpression to the poor outcome in
AA patients. Likewise, a comprehensive transcriptomic analysis that
detected the upregulation of specific gene set including SOS1 in a large
cohort of tumor samples from women with locally advanced cervical
cancer (LACC) identified the overexpressed genes as potential new
therapeutic targets which could be relevant for the clinical outcome of
LACC patients [243]. SOS1 was also the most frequently upregulated
gene detected by microarray profiling in a cohort of Egyptian bladder
cancer patients, suggesting its potential usefulness as a molecular bio-
marker of target for these patients [244]. SOS1 has also been shown to
be part of a set of 10 differentially expressed, cross-talk genes from
important signaling pathways involved in hepatocellular carcinomas
(HCC) that have been proposed to predict HCC prognosis and also
provide potential biomarkers or therapeutic targets for HCC [245].
SOS1 has also been identified as a member of a network of 14 differ-
entially expressed genes involved in inflammatory-mediated mechan-
isms in colorectal cancer (CRC) that has been postulated as a potential
prognostic marker for this tumoral disease [246]. The significantly
upregulated levels of circulating RNA for SOS1 detected by means of
next generation sequencing in the plasma of melanoma patients have
also been validated as a potential novel RNA-based biomarker for di-
agnostic use [34]. Finally, a recent report has also demonstrated that
enhanced expression of SOS1 is predictive of poor prognosis in uveal
malignant melanoma patients [37].
In sharp contrast to SOS1, and despite the similar expression pat-
terns of the two SOS family members, there are significantly fewer re-
ports describing specific associations of SOS2 gene alterations with
sporadic tumors (https://www.intogen.org/search?gene=SOS2). In
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particular, direct exome sequencing has detected the presence of so-
matic missense SOS2 mutations in 3.1% of gallblader carcinomas
samples tested [247]. Similarly, exome sequencing of desmoplastic
melanomas characterized by a high mutation burden did not find the
typical BRAF or NRAS mutations occurring in regular melanomas, but
frequent activating mutations in components of RAS-ERK pathways
including, in particular, SOS2 [248]. Finally, recent analysis of gene
expression profiles in the TCGA database has reported MuD-dependent
upregulation of SOS2 expression in cohorts of TCGA glioblastomas
(GBM), and a correlation between high expression of the two genes and
longer survival of proneural GBM patients [249]. An updated catalog of
somatic mutations in the SOS2 gene detected in many different tumor
types can be found in the COSMIC database, where ~8% of SOS2
mutated samples correspond to synonymous substitutions, ~38% cor-
respond to missense mutations and ~4% correspond to nonsense sub-
stitutions (https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=
SOS2#genome-browser).
6. SOS GEFs in the clinic
6.1. SOS as biomarkers and therapy targets
Despite their low frequency in comparison to other oncogenic dri-
vers, the presence of distinct (inherited or sporadic) gene alterations of
SOS1 or SOS2 in specific RASopathies [30,31] and sporadic tumors
[210,211,213,250] supports the use of RNA or protein probes for these
genes as potentially useful biomarkers for diagnosis or prognosis of all
those diseases. In fact, a number of recent reports have already docu-
mented the clinical prognostic value of the differential expression of
SOS1 for specific subsets of patients with QNBC, LACC, BLCA, HCC,
CRC, melanoma or uveal melanoma [34,37,241–243,245,246].
In addition, the SOS GEFs are also being increasingly considered as
worthy therapy targets based on the fact that all inherited RASopathies
and sporadic cancers harboring gain-of-function SOS1/2 gene altera-
tions share the dysregulation of RTK-RAS-ERK signalling pathways as a
common, underlying physiopathological mechanism. Indeed, the cen-
tral position played by SOS GEFs in control and regulation of RAS ac-
tivation and signalling suggests that SOS GEFs may be considered as
potential therapy targets not only in the reduced percentage of tumors
bearing recurrent, gain-of-function SOS mutations, but also in other
more frequent RAS-dependent tumors (lacking SOS mutations but
driven by mutations in EGFR, RAS, RAF, etc), where blockade of SOS
action may be of therapeutic benefit.
Based on frequency and overall clinical impact, the use of SOS1 as a
therapy target may be especially relevant in the case of NS-related and
HGF-related malignancies, as well as in sporadic cancers driven by any
oncogenic mutation causing activation of the RAS signalling pathway.
This is so because, although oncogenic RAS proteins are constitutively
activated (not needing, in theory, the action of upstream GEFs to be-
come GTP-loaded), seminal research from Bar Sagi´s laboratory [39,40]
Fig. 4. SOS mutations in cancer.
Schematic representation of different somatic mutations affecting the indicated domains of hSOS1 (https://www.intogen.org/search?gene=SOS1) or hSOS2
(https://www.intogen.org/search?gene=SOS2) that have been identified by the intOGen cancer mutation browser in different sporadic cancers including AML
(Acute Myeloid Leukemia), BLCA (Urothelial Bladder Cancer), LGG (Lower Grade Glioma), LIHC (Liver Hepatocellular Carcinoma), LUAD (Lung Adenocarcinoma),
LUSC (Lung Squamous Cell Carcinoma), SKMC (Cutaneous Melanoma) and UCEC (Uterine Corpus Endometrial Carcinoma) as indicated. Missense (blue), synon-
ymous (pink) and truncating (red) mutations are represented here. Location of recurrent mutations detected at higher frequency is indicated. The higher frequency of
recurrent N233Y/S mutations in hSOS1 allows for their consideration as bona fide oncogenic drivers in LUAD and UCEC.
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has demonstrated that the cross-activation of WT RAS (which is SOS-
dependent) by oncogenically mutated RAS is of critical importance for
tumorigenic development in mutant RAS-driven tumors. Consistent
with those observations, our analyses of single and double SOS1-KO
and SOS2-KO mouse strains have demonstrated that SOS1 depletion
significantly reduces BCR-ABL-induced leukemogenesis [28] and
DMBA/TPA-induced skin tumors [26], thus confirming the critical role
of SOS1 in those tumorigenic processes.
The clinical usefulness of targeting SOS is further supported by a
report highlighting the unique dependence on SOS1 of KRAS(G12D)-
induced leukemogenesis by showing that SOS1 deletion ameliorates
KRAS-induced mieloproliferative neoplasm phenotypes and prolongs
survival of KRAS G12D/+ mice [29]. Likewise, siRNA-based genetic
targeting of SOS1 and SOS2 (as well pharmacological targeting of
SHP2) has been shown to enhance efficacy of MEK inhibition in KRAS-
amplified gastroesophageal models in vitro and in vivo [38,251–253]. It
has also been reported that deficiency of any individual component of
the SOS1-EPS8-E3B1 complex correlates directly with loss of metastatic
capacity of ovarian tumors [36].
Furthermore, analysis of primary cells derived from single and
double SOS1-KO and SOS2-KO mice has shown reduced cell prolifera-
tion rates and increased intracellular oxidative stress and mitochondrial
dysfunction [23,25], as well as remarkable phenotypic similarities be-
tween RAS-less and SOS-less cells [254,255]. These observations at the
cellular level also support the notion of SOS1/2 proteins as meaningful
therapy targets in KRAS-driven (and also EGFR-driven) tumors since,
according to them, it is not unreasonable to expect that the inhibition of
SOS1/2 GEFs activity by specific inhibitors may, on one side inhibit
tumor progression and, on the other, increase intracellular ROS pro-
duction and alter mitochondrial metabolism thus triggering pro-
grammed cell death in the treated tumors. These encouraging, initial
observations have fostered the many different efforts currently ongoing
in industry and academy to develop specific inhibitor of SOS1/2 GEFs
as an approach to block hyperactivation of the RAS pathway in tumors.
6.2. Targeting aberrant RAS signaling in tumors
The RTK-SOS-RAS-ERK pathway is the most frequently altered sig-
naling pathway in human tumors and activating RAS mutations are
found in about 25% of all cancers types. KRAS is the single most fre-
quently altered gene (~9% across samples), followed by BRAF (~7%)
and EGFR (~4%), and smaller percentages of activating mutations are
reported for other participants in the pathway including the NRAS
(~2%) and HRAS (~1%) oncogenes [33,43,256]. The most recent es-
timate of RAS mutation data in cancer databases cites overall fre-
quencies of 14.3% for KRAS, 3.1% for NRAS and 1.3% for HRAS [256].
Whereas a number of clinically effective drugs against EGFR- and
BRAF-driven tumors are already in use [257–259], much less success
has been achieved regarding mutant RAS-driven tumors after almost
four decades of intensive research [260–264]. Indeed, although the RAS
oncoproteins were frequently deemed as “undruggable” in recent years
[265,266], recent breakthroughs have started to challenge that per-
ception with the development of new anti-KRAS inhibitors that are
currently being tried under different stages/phases of clinical testing
[42,43] (Supplementary Table 5).
Although great expectations are now focused on the novel drugs
that target specific RAS oncogenic mutations such as the G12C muta-
tion [42,267–270], the array of promising new therapies directed at
inhibiting or attenuating oncogenic RAS signaling in tumors is not
limited to direct RAS oncoprotein inhibitors. Indeed, the recent re-
cognition of the critical functional role played by non-mutated, WT RAS
proteins in the context of mutant RAS cancers [39,41] has also paved
the way for additional, new therapeutic strategies focused on either
targeting various downstream effectors of RAS signaling [271] or dis-
rupting the interaction of RAS proteins with upstream signaling mole-
cules, including RTKs like the EGFR [258,259], the scaffolding
phosphatase SHP2 [38], or, particularly, the upstream SOS1/2 acti-
vating GEFs [42,43]. The following section highlights recent develop-
ments regarding novel approaches to downregulate RTK-RAS-ERK on-
cogenic signaling by specifically targeting the SOS1/2 GEFs with novel
compounds capable of directly blocking the intrinsic GEF activity of
SOS proteins or impairing the functional interactions between RAS and
SOS within the SOS:RAS complex.
6.3. Inhibiting SOS function and SOS-RAS interactions
Different approaches to SOS inhibition, including efforts (i) to
physically remove SOS from the tumoral context, as well as attempts to
block (ii) the intrinsic GEF enzymatic activity of SOS proteins or (iii) the
functionality of SOS:RAS interactions, have been tried in recent years in
the context of attempts to target or attenuate oncogenic signaling in
tumors harboring altered RTK-RAS-ERK signaling pathways [272]
(Supplementary Table 5).
6.3.1. SOS GEF depletion/removal
The initial proof of concept of the efficacy of targeting SOS in tu-
mors was provided by experimental reports where physical elimination
of SOS1 resulted in significant impairment of tumor development.
Specifically, depletion of SOS1 in KO mouse strains has been shown to
result in significant reduction of skin tumor formation [26] and leu-
kemogenesis [28,29]. Consistently, silencing of SOS1 by means of
siRNA or shRNA also produces significant therapeutic benefits in gas-
troesophageal tumors [38]. Interestingly, the miRNAs modulating SOS
expression can be chemically modified in order to increase its activity,
thus raising the possibility of using them as therapeutical agents in
different pathological contexts. This is the case, for example, with
chemically modified miR-143 (miR-143#12), which shows increased
affinity for hSOS1 and displays measurable anti-cancer effects on
bladder cancer upon systemic or intravesical treatment [273] or on
colon carcinoma DLD-1 cells [274] (Supplementary Table 1).
Physically impairing, blocking or displacing SOS proteins from in-
teraction with their physiological intracellular protein partners or cor-
rect subcellular locations has also proven to be therapeutically bene-
ficial. For example, transfected VPS8 has been shown to directly bind
SOS1 and inhibit SOS1-RAS signaling initiated by peptide growth fac-
tors including EGF [275].
6.3.2. High molecular weight (HMW) inhibitors of SOS protein-protein
interactions (PPI)
The use of HMW reagents (natural or synthetic) aimed at blocking
or impairing PPI between SOS GEFs and their physiological RAS targets
or signaling partners has also proven to be an effective approach to
inhibit correct SOS-RAS complex formation and subsequent down-
stream oncogenic signaling. Early experiments showed that permeable
synthetic orthosteric peptide mimetics are able to disrupt the interac-
tion between SOS-αH with the switch I loop of RAS resulting in sig-
nificant blockade of SOS-RAS interaction and efficient reduction of
RAS-ERK activation upon stimulation [276]. Likewise, hydrocarbon-
stapled, stabilized α-helices of SOS1 (SAH-SOS1) were shown to di-
rectly bind and inhibit WT and mutant forms of KRAS [277]. More
recently, the introduction of d-amino acids in the sequence of these
peptides has improved their affinity and specificity, giving rise to re-
agents able to specifically bind to KRAS (G12C) and induce selective
apoptosis in cells harboring this RAS mutation [278]. Finally, another
HMW agent, the Bacillus pumilus ribonuclease Binase has been shown to
directly interact with endogenous KRAS and inhibit downstream ERK
signaling by reducing RAS interaction with its GEF SOS1 [279].
Approaches blocking the interaction of SOS with its physiological,
intracellular signaling partners may also provide effective ways to in-
hibit oncogenic RAS signaling. For example, a synthetic analog of
UCS15A, a potent inhibitor of proline-rich ligand-mediated PPI (PPLI)
produced by Streptomyces species, has been reported to block GRB2-
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SOS1 interaction and also inhibit MEK activity in vivo without causing
morphological changes to treated cells [280]. More recently, the effi-
cacy of other synthetic covalent inhibitors of GRB2:SOS1 interaction
has also been proven in vivo, resulting in migration inhibition and cell
death in breast cancer cells [281]. Interestingly, RMC-4550, an ami-
nopiperidine-derived small-molecule used as an allosteric SHP2 phos-
phatase inhibitor has also been shown to disrupt the SHP2-GRB2-SOS1
complex module and decrease oncogenic RAS-ERK signaling and cancer
growth by disrupting SOS1-mediated RAS•GTP loading in RAS-driven
cancers [253].
6.3.3. Small-molecule SOS inhibitors active against RAS-driven tumors
So far, the most promising approaches to modulating or down-
regulating SOS activity in tumors in a clinical setting appear to derive
from the rational design of small-molecule inhibitors able to target di-
rectly its intrinsic RASGEF enzymatic activity [282] or its functional,
dynamic interaction with RAS targets [42,272] (Supplementary
Table 5).
In this regard, Zheng´s laboratory provided a solid proof of concept
for rational design of small-molecule inhibitors targeting RASGEF en-
zymatic activity by using in vitro GEF assays and a high throughput
screening exchange assay platform to identify benzopyran-based mo-
lecules and other compounds capable of directly targeting the GEF
enzymatic activity of SOS proteins by binding to specific residues in its
catalytic region [282].
On the other hand, most screenings for small-molecule inhibitors
have focused on targeting the RAS:SOS complex, searching for in-
hibitors able to block (i) the formation or stabilization of this complex
or (ii) some of its internal conformational and functional dynamic in-
teractions between the SOS and RAS partners [88,272,283]. In this
regard, when evaluating the outcome of this type of screenings it is
relevant to ascertain (i) which one of the three possible regions of the
complex (RAS moiety, SOS moiety or the RAS:SOS interphase) is bound
by the small-molecules identified, (ii) the chemical nature of these
compounds, and (iii) whether or not the binding to the complex is re-
versible or irreversible. The commonly accepted wisdom suggests that
the most efficacious inhibitors from the clinical point of view are
covalent inhibitors binding irreversibly to specific mutant RAS proteins
in the complex [42,284,285].
Very different chemical structures have been identified over the
years in the multiple screenings performed by various laboratories in
search of small molecules able to inhibit SOS-RAS functional interac-
tions within the SOS:RAS complex. For example, as a result of some of
the early screenings, various D-arabinose-derived compounds [286] as
well as different andrographolide derivatives [287] or bisphenol com-
pounds [288] were identified that were capable of inhibiting SOS1-
mediated nucleotide exchange in the complex by binding to a site near
to switch-II region of RAS proteins. Interestingly, bisphenol A has been
recently demonstrated to induce increase of SOS1 expression and pro-
liferation in human uterine leiomyoma cells [289]. Likewise, other
screens have identified structurally different Indole- and sulfonamide-
derived compounds that bind to the same pocket site in the SOS:RAS
complex and specifically inhibit SOS-mediated RAS activation
[290,291].
Covalent compounds that act irreversibly are the most potent in-
hibitors able to restrain SOS:RAS interaction. Consistent with this view,
a X-ray crystallography-based analysis of an extensive collection of
compounds binding to the RAS:SOS complex led to the discovery of
three distinct fragment binding sites on this complex. Interestingly, the
compounds binding in the inner regions of SOS or in the SOS:RAS in-
terface did it reversibly and were not sufficiently potent inhibitors. In
contrast, the NEM-based compounds binding in the RAS part of the
complex were shown to produce covalent modification of Cys118 and
result in effective inhibition of the exchange of GDP for GTP in the WT
and mutant (G12C and G12V) RAS proteins [284].
Interestingly, small-molecule compounds have also been reported
that bind to the RAS:SOS complex and increase the rate of SOS-medi-
ated nucleotide exchange. X-ray crystallography analysis reveals that
these compounds bind in a hydrophobic pocket in the CDC25H domain
of SOS that is adjacent to the Switch II region of RAS in the SOS:RAS
complex [292,293]. Mechanistically, these SOS1 agonists elicit biphasic
modulation of ERK phosphorylation and simultaneous inhibition of
AKT in treated cells [133,294–297], further highlighting how a SOS
pocket may be exploited to modulate RAS signaling.
The most clinically effective in vivo inhibitors initially identified
belonged to the wide family of compounds capable of binding irrever-
sibly in a previously unrecognized switch II pocket to oncogenic
RASG12C mutant proteins that were initially discovered in Shokat´s la-
boratory [298] and later developed and improved refined further in his
own lab and a number of other laboratories and pharma companies
[42,285]. Different mutation-specific compounds targeting G12C (in-
cluding ARS853, AMG510, 2C07, MRTX849, etc) have produced suc-
cessful in vivo results, demonstrating their antitumor activity and
therapeutic benefit in various preclinical and clinical tests
[45,46,48,50,299,300].
Furthermore, while the search remains active for inhibitors tar-
geting other specific RAS oncogenic mutations, like G12D or G12V,
recent reports have described the discovery of novel small-molecule
inhibitors capable of selectively inhibiting the functional interaction of
SOS1 with all different RAS isoforms, thus making it possible to si-
multaneously target all active and inactive forms of KRAS in vivo [42]
(Supplementary Table 5). Mechanistically, one of these new direct in-
hibitors (BI-2852) has been shown to bind with nanomolar affinity to a
newly named switch I/II pocket of RAS in both the ON and OFF states,
thus being able to block interaction with all activating partners and
effectors, as well as inducing nonfunctional dimers of KRAS [47,49,52].
In contrast, other recently described inhibitors (including BAY293, BI-
3406, BI-170192, etc) have been shown to bind directly to the SOS
partner of the RAS:SOS complex and to be able inhibit the growth of
multiple, different KRAS G12 and G13 mutant tumor cell lines [44,51]
(NCI trial NCT04111458). The possibility of future development of
inhibitors able to discriminate between SOS1 and SOS2 may also offer
additional therapeutic flexibility and possibilities to the arsenal of small
molecules regarding in vivo antitumor action.
7. Concluding remarks
We summarized in this review a collection of experimental evidence
that together support the identification of SOS1 and SOS2 as the most
universal and widely expressed family of GEF activators of the members
of the RAS family of proteins (HRAS, NRAS, KRAS) in metazoan cells
that are also able to activate RAC1 in certain contexts. In this regard, it
is evident that the SOS GEFs play a central regulatory role in RTK-RAS/
RAC-ERK signaling in all metazoan cells.
We described initially the very high homologies exhibited by SOS1
and SOS2 with regards to the structural and regulatory aspects of their
encoding genes and protein products. However, despite those homo-
logies, most functional studies have demonstrated the functional pre-
dominance of SOS1 over SOS2 in most physiological and pathological
contexts, although some residual, partial functional redundancy was
still observable in different experimental settings.
Interestingly, a series of activating, gain of function mutations, oc-
curring preferentially in SOS1 genes, have been found in association
with various inherited RASopathies and with different sporadic cancers.
The fact that these pathological conditions share the dysregulation of
RAS-ERK signaling as a common, underlying mechanistic feature in-
dicates that SOS GEF function is critical, not only for regulation of
physiological RAS signaling in normal cells but also for pathological,
oncogenic signaling in tumors.
In this regard, the specific association of SOS1 mutations with dis-
tinct RASopathies and/or tumors, as well as the observation that SOS1
depletion blocks carcinogenesis in animal models, support the
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consideration of SOS1 as a potential marker and/or therapy target in
those pathological conditions. On the other hand, the central regulatory
role played by SOS GEFs in RAS signaling, together with the seminal
demonstration that SOS-mediated activation of WT RAS is critical for
tumorigenic development in mutant RAS-driven tumors, expands the
usefulness of SOS GEFs as potential therapy targets. In this regard, this
potential usefulness would apply not only to the low percentage of
RASopathies and tumors bearing gain-of-function SOS mutations but
also to all RAS-mutant tumors or RTK-dependent tumors that depend on
the activation of WT RAS by SOS for their development.
Happily, a number of small-molecule, specific SOS inhibitors have
been recently described and shown high promise in preclinical and
clinical tests, thus raising hope that the possible modulation of SOS
function by means of these inhibitors may help with the clinical man-
agement of RAS-driven and even RTK-driven tumors. Furthermore,
given the partial functional redundancy exhibited by SOS1 and SOS2 in
different biological settings, it is likely that the eventual development of
specific SOS1 or SOS2 inhibitors may significantly enrich the possibi-
lities of clinical intervention for the management and therapy of dif-
ferent types of RAS-dependent tumors.
Exciting times certainly lie ahead to try and prove the anticancer
effectiveness of small-molecule SOS1 and/or SOS2 inhibitors used alone
or in combination with other inhibitors acting at different points of the
RAS-ERK pathway or other oncogenic pathways.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbcan.2020.188445.
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